Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Gonzalez Website

Frank J. Gonzalez, Ph.D.

Selected Publications

1)  Manna SK, Tanaka N, Krausz KW, Haznadar M, Xue X, Matsubara T, Bowman ED, Fearon ER, Harris CC, Shah YM, Gonzalez FJ.
Biomarkers of coordinate metabolic reprogramming in colorectal tumors in mice and humans.
Gastroenterology. 2014.
In Press. [Journal]
2)  Liu A, Krausz KW, Fang Z, Brocker C, Qu A, Gonzalez FJ.
Gemfibrozil disrupts lysophosphatidylcholine and bile acid homeostasis via PPARalpha and its relevance to hepatotoxicity.
Arch. Toxicol. 2014.
In Press. [Journal]
3)  Lee JK, Chung HJ, Fischer L, Fischer J, Gonzalez FJ, Jeong H.
Human placental lactogen induces CYP2E1 expression Via PI 3-kinase pathway in female human hepatocytes.
Drug Metab. Dispos. 2014.
In Press. [Journal]
4)  Fang Z, Krausz KW, Nagaoka K, Tanaka N, Gowda K, Amin SG, Perdew GH, Gonzalez FJ.
In vivo application of the pure aryl hydrocarbon receptor antagonist GNF-351 is limited to the gastrointestinal track.
Br. J. Pharmacol. 2014.
In Press. [Journal]
5)  Ramakrishnan SK, Taylor M, Qu A, Ahn S, Suresh MV, Raghavendran K, Gonzalez FJ, Shah YM.
Loss of Von Hippel-Lindau (VHL) increases systemic cholesterol level through targeting HIF-2a and regulation of bile acid homeostasis.
Mol. Cell. Biol. 2014.
In Press. [Journal]
6)  Ciappio ED, Krausz KW, Rochman M, Furusawa T, Bonzo JA, Tessarollo L, Gonzalez FJ, Bustin M.
Metabolomics reveals a role for the chromatin-binding protein HMGN5 in glutathione metabolism.
PLoS ONE. 9: e84583, 2014.
7)  Koh KH, Pan X, Shen H, Arnold SL, Yu A, Gonzalez FJ, Isoherranen N, Jeong H.
Altered expression of small heterodimer partner governs cytochrome P450 (CYP) 2D6 induction during pregnancy in CYP2D6-humanized mice.
J. Biol. Chem. 2013.
In Press. [Journal]
8)  Kondo Y, Iwao T, Nakamura K, Sasaki T, Takahashi S, Kamada N, Matsubara T, Gonzalez FJ, Akutsu H, Miyagawa Y, Okita H, Kiyokawa N, Toyoda M, Umezawa A, Nagata K, Matsunaga T, Ohmori S.
An efficient method for differentiation of human induced pluripotent stem cells into hepatocyte-like cells retaining drug metabolizing activity.
Drug Metab. Pharmacokinet. 2013.
In Press. [Journal]
9)  Patterson AD, Carlson BA, Li F, Bonzo JA, Yoo M, Krausz KW, Conrad M, Chen C, Gonzalez FJ, Hatfield DL.
Disruption of thioredoxin reductase 1 protects mice from acute acetaminophen-induced hepatotoxicity through enhanced NRF2 activity.
Chem. Res. Toxicol. 2013.
In Press. [Journal]
10)  Cheng J, Chen C, Kristopher KW, Manna SK, Scerba M, Friedman FK, Luecke H, Idle JR, Gonzalez FJ.
Identification of 2-piperidone as a biomarker of CYP2E1 activity through metabolomic phenotyping.
Toxicol. Sci. 2013.
In Press. [Journal]
11)  Cheng J, Zhen Y, Miksys S, Beyoglu D, Krausz KW, Tyndale R, Yu A, Idle JR, Gonzalez FJ.
Potential role of CYP2D6 in the central nervous system.
Xenobiotica. 2013.
In Press. [Journal]
12)  Mejia-Garcia A, Sanchez-Ocampo EM, Galindo-Gomez S, Shibayama M, Reyes-Hernandez O, Guzman-Leon S, Gonzalez FJ, Elizondo G.
2,3,7,8-Tetrachlorodibenzo-p-dioxin enhances CCl4-induced hepatotoxicity in an aryl hydrocarbon receptor-dependent manner.
Xenobiotica. 43: 161-8, 2013.
13)  Fang ZZ, He RR, Cao YF, Tanaka N, Jiang C, Krausz KW, Qi Y, Dong PP, Ai CZ, Sun XY, Hong M, Ge GB, Gonzalez FJ, Ma XC, Sun HZ.
A model of in vitro UDP-glucuronosyltransferase inhibition by bile acids predicts possible metabolic disorders.
J. Lipid Res. 54: 3334-44, 2013.
14)  Albrecht PP, Torsell NE, Krishnan P, Ehresman DJ, Frame SR, Chang S, Butenhoff JL, Kennedy GL, Gonzalez FJ, Peters JM.
A species difference in the peroxisome proliferator-activated receptor alpha-dependent response to the developmental effects of perfluorooctanoic acid.
Toxicol. Sci. 131: 568-82, 2013.
15)  Lau SM, Cha KM, Karunatillake A, Stokes RA, Cheng K, McLean M, Cheung NW, Gonzalez FJ, Gunton JE.
Beta-cell ARNT is required for normal glucose tolerance in murine pregnancy.
PLoS ONE. 8: e77419, 2013.
16)  Wejksza K, Lee-Chang C, Bodogai M, Bonzo J, Gonzalez FJ, Lehrmann E, Becker K, Biragyn A.
Cancer-produced metabolites of 5-lipoxygenase induce tumor-evoked regulatory B cells via peroxisome proliferator-activated receptor alpha.
J. Immunol. 190: 2575-84, 2013.
17)  Ito S, Satoh J, Matsubara T, Shah YM, Ahn SH, Anderson CR, Shan W, Peters JM, Gonzalez FJ.
Cholestasis induces reversible accumulation of periplakin in mouse liver.
BMC Gastroenterol. 13: 116, 2013.
18)  Kanbe H, Kamijo Y, Nakajima T, Tanaka N, Sugiyama E, Wang L, Fang ZZ, Hara A, Gonzalez FJ, Aoyama T.
Chronic ethanol consumption decreases serum sulfatide levels by suppressing hepatic cerebroside sulfotransferase expression in mice.
Arch. Toxicol. 2013.
19)  Abdelmegeed MA, Banerjee A, Jang S, Yoo SH, Yun JW, Gonzalez FJ, Keshavarzian A, Song BJ.
CYP2E1 potentiates binge alcohol-induced gut leakiness, steatohepatitis, and apoptosis.
Free Radic. Biol. Med. 65C: 1238-1245, 2013.
20)  Cheng J, Krausz KW, Li F, Ma X, Gonzalez FJ.
CYP2E1-dependent elevation of serum cholesterol, triglycerides, and hepatic bile acids by isoniazid.
Toxicol. Appl. Pharmacol. 266: 245-53, 2013.
21)  Johnson CH, Bonzo JA, Cheng J, Krausz KW, Kang DW, Luecke H, Idle JR, Gonzalez FJ.
Cytochrome P450 regulation by a-tocopherol in Pxr-null and PXR-humanized mice.
Drug Metab. Dispos. 41: 406-13, 2013.
22)  Nakashima R, Hayashi Y, Md K, Jia X, Wang D, Naito H, Ito Y, Kamijima M, Gonzalez FJ, Nakajima T.
Exposure to DEHP decreased four fatty acid levels in plasma of prepartum mice.
Toxicology. 309: 52-60, 2013.
23)  Aibara D, Matsusue K, Matsuo K, Takiguchi S, Gonzalez FJ, Yamano S.
Expression of hepatic fat-specific protein 27 depends on the specific etiology of Fatty liver.
Biol. Pharm. Bull. 36: 1766-72, 2013.
24)  Matsubara T, Li F, Gonzalez FJ.
FXR signaling in the enterohepatic system.
Mol. Cell. Endocrinol. 368: 17-29, 2013.
25)  Kim JH, Qu A, Reddy JK, Gao B, Gonzalez FJ.
Hepatic oxidative stress activates the Gadd45b gene via degradation of the transcriptional repressor STAT3.
Hepatology. 2013.
26)  Li F, Lu J, Cheng J, Wang L, Matsubara T, Csanaky IL, Klaassen CD, Gonzalez FJ, Ma X.
Human PXR modulates hepatotoxicity associated with rifampicin and isoniazid co-therapy.
Nat. Med. 19: 418-20, 2013.
27)  Jiang C, Kim JH, Li F, Qu A, Gavrilova O, Shah YM, Gonzalez FJ.
Hypoxia-inducible factor 1a regulates a SOCS3-STAT3-adiponectin signal transduction pathway in adipocytes.
J. Biol. Chem. 288: 3844-57, 2013.
28)  Li HH, Doiron K, Patterson AD, Gonzalez FJ, Fornace Jr AJ.
Identification of serum insulin-like growth factor binding protein 1 as diagnostic biomarker for early-stage alcohol-induced liver disease.
J Transl Med. 11: 266, 2013.
29)  Kim J, Yamaori S, Tanabe T, Johnson CH, Krausz KW, Kato S, Gonzalez FJ.
Implication of intestinal VDR deficiency in inflammatory bowel disease.
Biochim. Biophys. Acta. 1830: 2118-28, 2013.
30)  Cheng J, Fang ZZ, Kim JH, Krausz KW, Tanaka N, Chiang JY, Gonzalez FJ.
Intestinal CYP3A4 protects against lithocholic acid-induced hepatotoxicity in vitamin D receptor intestine-deficient mice.
J. Lipid Res. 2013.
31)  Manna SK, Krausz KW, Bonzo JA, Idle JR, Gonzalez FJ.
Metabolomics reveals aging-associated attenuation of noninvasive radiation biomarkers in mice: potential role of polyamine catabolism and incoherent DNA damage-repair.
J. Proteome Res. 12: 2269-81, 2013.
32)  Li F, Patterson AD, Krausz KW, Jiang C, Bi H, Sowers AL, Cook JA, Mitchell JB, Gonzalez FJ.
Metabolomics Reveals that Tumor Xenografts Induce Liver Dysfunction.
Mol. Cell Proteomics. 2013.
33)  Fang ZZ, Krausz KW, Tanaka N, Li F, Qu A, Idle JR, Gonzalez FJ.
Metabolomics reveals trichloroacetate as a major contributor to trichloroethylene-induced metabolic alterations in mouse urine and serum.
Arch. Toxicol. 2013.
34)  Montanez JE, Peters JM, Correll JB, Gonzalez FJ, Patterson AD.
Metabolomics: an essential tool to understand the function of peroxisome proliferator-activated receptor alpha.
Toxicol Pathol. 41: 410-8, 2013.
35)  Li F, Jiang C, Krausz KW, Li Y, Albert I, Hao H, Fabre KM, Mitchell JB, Patterson AD, Gonzalez FJ.
Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity.
Nat Commun. 4: 2384, 2013.
36)  Feuermann Y, Kang K, Gavrilova O, Haetscher N, Jin Jang S, Yoo KH, Jiang C, Gonzalez FJ, Robinson GW, Hennighausen L.
MiR-193b and miR-365-1 are not required for the development and function of brown fat in the mouse.
RNA Biol. 10, 2013.
37)  Dong H, Shertzer HG, Genter MB, Gonzalez FJ, Vasiliou V, Jefcoate C, Nebert DW.
Mitochondrial targeting of mouse NQO1 and CYP1B1 proteins.
Biochem. Biophys. Res. Commun. 435: 727-32, 2013.
38)  Bi H, Krausz KW, Manna SK, Li F, Johnson CH, Gonzalez FJ.
Optimization of harvesting, extraction, and analytical protocols for UPLC-ESI-MS-based metabolomic analysis of adherent mammalian cancer cells.
Anal Bioanal Chem. 405: 5279-89, 2013.
39)  Goto K, Iso T, Hanaoka H, Yamaguchi A, Suga T, Hattori A, Irie Y, Shinagawa Y, Matsui H, Syamsunarno MR, Matsui M, Haque A, Arai M, Kunimoto F, Yokoyama T, Endo K, Gonzalez FJ, Kurabayashi M.
Peroxisome proliferator-activated receptor-gamma in capillary endothelia promotes fatty acid uptake by heart during long-term fasting.
J Am Heart Assoc. 2: e004861, 2013.
40)  Liu H, Fang Y, Hu Y, Gonzalez FJ, Fang J, Wan YY.
PPARbeta regulates liver regeneration by modulating Akt and E2f signaling.
PLoS ONE. 8: e65644, 2013.
41)  Zhu B, Ferry CH, Blazanin N, Bility MT, Khozoie C, Kang BH, Glick AB, Gonzalez FJ, Peters JM.
PPARß/d promotes HRAS-induced senescence and tumor suppression by potentiating p-ERK and repressing p-AKT signaling.
Oncogene. 2013.
42)  Marchesi C, Rehman A, Rautureau Y, Kasal DA, Briet M, Leibowitz A, Simeone SM, Ebrahimian T, Neves MF, Offermanns S, Gonzalez FJ, Paradis P, Schiffrin EL.
Protective role of vascular smooth muscle cell PPARgamma in angiotensin II-induced vascular disease.
Cardiovasc. Res. 97: 562-70, 2013.
43)  Holmstock N, Gonzalez FJ, Baes M, Annaert P, Augustijns P.
PXR/CYP3A4-humanized mice for studying drug-drug interactions involving intestinal P-glycoprotein.
Mol. Pharm. 10: 1056-62, 2013.
44)  Roy A, Jana M, Corbett GT, Ramaswamy S, Kordower JH, Gonzalez FJ, Pahan K.
Regulation of cyclic AMP response element binding and hippocampal plasticity-related genes by peroxisome proliferator-activated receptor a.
Cell Rep. 4: 724-37, 2013.
45)  Safdar H, Cleuren AC, Cheung KL, Gonzalez FJ, Vos HL, Inoue Y, Reitsma PH, van Vlijmen BJ.
Regulation of the f11, klkb1, cyp4v3 gene cluster in livers of metabolically challenged mice.
PLoS ONE. 8: e74637, 2013.
46)  Qu A, Jiang C, Cai Y, Kim JH, Tanaka N, Ward JM, Shah YM, Gonzalez FJ.
Role of Myc in hepatocellular proliferation and hepatocarcinogenesis.
J. Hepatol. 2013.
47)  Konstandi M, Shah YM, Matsubara T, Gonzalez FJ.
Role of PPARa and HNF4a in stress-mediated alterations in lipid homeostasis.
PLoS ONE. 8: e70675, 2013.
48)  Spruiell K, Richardson RM, Cullen JM, Awumey EM, Gonzalez FJ, Gyamfi MA.
Role of pregnane X receptor in obesity and glucose homeostasis in male mice.
J. Biol. Chem. 2013.
49)  Konstandi M, Cheng J, Gonzalez FJ.
Sex steroid hormones regulate constitutive expression of Cyp2e1 in female mouse liver.
Am. J. Physiol. Endocrinol. Metab. 2013.
50)  Li F, Pang X, Krausz KW, Jiang C, Chen C, Cook JA, Krishna MC, Mitchell JB, Gonzalez FJ, Patterson AD.
Stable isotope- and mass spectrometry-based metabolomics as tools in drug metabolism: a study expanding tempol pharmacology.
J. Proteome Res. 12: 1369-76, 2013.
51)  Bi H, Li F, Krausz KW, Qu A, Johnson CH, Gonzalez FJ.
Targeted metabolomics of serum acylcarnitines evaluates hepatoprotective effect of wuzhi tablet (schisandra sphenanthera extract) against acute acetaminophen toxicity.
Evid Based Complement Alternat Med. 2013: 985257, 2013.
52)  Sato S, Shirakawa H, Tomita S, Tohkin M, Gonzalez FJ, Komai M.
The aryl hydrocarbon receptor and glucocorticoid receptor interact to activate human metallothionein 2A.
Toxicol. Appl. Pharmacol. 273: 90-9, 2013.
53)  Viswakarma N, Jia Y, Bai L, Gao Q, Lin B, Zhang X, Misra P, Rana A, Jain S, Gonzalez FJ, Zhu YJ, Thimmapaya B, Reddy JK.
The Med1 subunit of the mediator complex induces liver cell proliferation and is phosphorylated by AMP kinase.
J. Biol. Chem. 288: 27898-911, 2013.
54)  Singh A, Happel C, Manna SK, Acquaah-Mensah G, Carrerero J, Kumar S, Nasipuri P, Krausz KW, Wakabayashi N, Dewi R, Boros LG, Gonzalez FJ, Gabrielson E, Wong KK, Girnun G, Biswal S.
Transcription factor NRF2 regulates miR-1 and miR-206 to drive tumorigenesis.
J. Clin. Invest. 123: 2921-34, 2013.
55)  Zhang Y, Li F, Patterson AD, Wang Y, Krausz KW, Neale G, Thomas S, Nachagari D, Vogel P, Vore M, Gonzalez FJ, Schuetz JD.
Abcb11 deficiency unduces cholestasis coupled to impaired beta-fatty acid oxidation in mice.
J Biol Chem. 287: 24784-94, 2012.
56)  Khozoie C, Borland MG, Zhu B, Baek S, John S, Hager GL, Shah YM, Gonzalez FJ, Peters JM.
Analysis of the peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) cistrome reveals novel co-regulatory role of ATF4.
BMC Genomics. 13: 665, 2012.
57)  Sato Y, Hatta M, Karim MF, Sawa T, Wei F, Sato S, Magnuson MA, Gonzalez FJ, Tomizawa K, Akaike T, Yoshizawa T, Yamagata K.
Anks4b, a novel target of HNF4alpha interacts with GRP78 and regulates endoplasmic reticulum stress-induced apoptosis in pancreatic beta-cells.
J Biol Chem. 287: 23236-45, 2012.
58)  Dufer M, Horth K, Wagner R, Schittenhelm B, Prowald S, Wagner TF, Oberwinkler J, Lukowski R, Gonzalez FJ, Krippeit-Drews P, Drews G.
Bile acids acutely stimulate insulin secretion of mouse beta-cells via farnesoid X receptor activation and KATP channel inhibition.
Diabetes. 61: 1479-89, 2012.
59)  Cheng J, Krausz KW, Tanaka N, Gonzalez FJ.
Chronic exposure to rifaximin causes hepatic steatosis in pregnane X receptor-humanized mice.
Toxicol Sci. 129: 456-68, 2012.
60)  Bongard RD, Myers CR, Lindemer BJ, Baumgardt S, Gonzalez FJ, Merker MP.
Coenzyme Q1 as a probe for mitochondrial complex I activity in the intact perfused hyperoxia-exposed wild-type and Nqo1-null mouse lung.
Am J Physiol Lung Cell Mol Physiol. 302: 949-58, 2012.
61)  Abdelmegeed MA, Banerjee A, Yoo SH, Jang S, Gonzalez FJ, Song BJ.
Critical role of cytochrome P450 2E1 (CYP2E1) in the development of high fat-induced non-alcoholic steatohepatitis.
J. Hepatol. 57: 860-6, 2012.
62)  Jennings BL, Anderson LJ, Estes AM, Yaghini FA, Fang XR, Porter J, Gonzalez FJ, Campbell WB, Malik KU.
Cytochrome P450 1B1 contributes to renal dysfunction and damage caused by angiotensin II in mice.
Hypertension. 59: 348-54, 2012.
63)  Jennings BL, Estes AM, Anderson LJ, Fang XR, Yaghini FA, Fan Z, Gonzalez FJ, Campbell WB, Malik KU.
Cytochrome P450 1B1 gene disruption minimizes deoxycorticosterone acetate-salt-induced hypertension and associated cardiac dysfunction and renal damage in mice.
Hypertension. 60: 1510-6, 2012.
64)  Qu A, Shah YM, Manna SK, Gonzalez FJ.
Disruption of endothelial peroxisome proliferator-activated receptor gamma accelerates diet-induced atherogenesis in LDL receptor-null mice.
Arterioscler. Thromb. Vasc. Biol. 32: 65-73, 2012.
65)  Tanaka N, Matsubara T, Krausz KW, Patterson AD, Gonzalez FJ.
Disruption of phospholipid and bile acid homeostasis in mice with nonalcoholic steatohepatitis.
Hepatology. 56: 118-29, 2012.
66)  Pang X, Cheng J, Kim J, Matsubara T, Krausz KW, Gonzalez FJ.
Expression and regulation of human fetal-specific CYP3A7 in mice.
Endocrinology. 153: 1453-63, 2012.
67)  Ghosh A, Corbett GT, Gonzalez FJ, Pahan K.
Gemfibrozil and fenofibrate, food and drug administration-approved lipid-lowering drugs, up-regulate tripeptidyl-peptidase 1 in brain cells via peroxisome proliferator-activated receptor alpha: Implications for late infantile batten disease therapy.
J Biol Chem. 287: 38922-35, 2012.
68)  Jana M, Mondal S, Gonzalez FJ, Pahan K.
Gemfibrozil, a lipid-lowering drug, increases myelin genes in human oligodendrocytes via peroxisome proliferator-activated receptor-alpha.
J Biol Chem. 287: 34134-48, 2012.
69)  Kimura T, Nakajima T, Kamijo Y, Tanaka N, Wang L, Hara A, Sugiyama E, Tanaka E, Gonzalez FJ, Aoyama T.
Hepatic cerebroside sulfotransferase is induced by PPARalpha activation in mice.
PPAR Res. 2012: 174932, 2012.
70)  Sarkar K, Cai Z, Gupta R, Parajuli N, Fox-Talbot K, Darshan MS, Gonzalez FJ, Semenza GL.
Hypoxia-inducible factor 1 transcriptional activity in endothelial cells is required for acute phase cardioprotection induced by ischemic preconditioning.
Proc. Natl. Acad. Sci. U.S.A. 109: 10504-9, 2012.
71)  Stokes RA, Cheng K, Deters N, Lau SM, Hawthorne WJ, O'Connell PJ, Stolp J, Grey S, Loudovaris T, Kay TW, Thomas HE, Gonzalez FJ, Gunton JE.
Hypoxia-inducible factor 1α (HIF-1α) potentiates β-cell survival after islet transplantation of human and mouse islets.
Cell Transplant. [Epub ahead of print], 2012.
72)  Xue X, Taylor M, Anderson E, Hao C, Qu A, Greenson JK, Zimmermann EM, Gonzalez FJ, Shah YM.
Hypoxia-inducible factor-2alpha activation promotes colorectal cancer progression by dysregulating iron homeostasis.
Cancer Res. 72: 2285-93, 2012.
73)  Fang ZZ, Krausz KW, Li F, Cheng J, Tanaka N, Gonzalez FJ.
Metabolic map and bioactivation of the anti-tumour drug noscapine.
Br. J. Pharmacol. 167: 1271-86, 2012.
74)  Matsubara T, Tanaka N, Krausz KW, Manna SK, Kang DW, Anderson ER, Luecke H, Patterson AD, Shah YM, Gonzalez FJ.
Metabolomics identifies an inflammatory cascade involved in dioxin- and diet-induced steatohepatitis.
Cell Metab. 16: 634-44, 2012.
75)  Li F, Patterson AD, Krausz KW, Tanaka N, Gonzalez FJ.
Metabolomics reveals an essential role for peroxisome proliferator-activated receptor alpha in bile acid homeostasis.
J. Lipid Res. 53: 1625-35, 2012.
76)  Li F, Patterson AD, Krausz KW, Dick B, Frey FJ, Gonzalez FJ, Idle JR.
Metabolomics reveals the metabolic map of procainamide in humans and mice.
Biochem. Pharmacol. 83: 1435-44, 2012.
77)  Safdar H, Cheung KL, Vos HL, Gonzalez FJ, Reitsma PH, Inoue Y, van Vlijmen BJ.
Modulation of mouse coagulation gene transcription following acute in vivo delivery of synthetic small interfering RNAs targeting HNF4alpha and C/EBPalpha.
PLoS ONE. 7: e38104, 2012.
78)  Menezes LF, Zhou F, Patterson AD, Piontek KB, Krausz KW, Gonzalez FJ, Germino GG.
Network analysis of a Pkd1-mouse model of autosomal dominant polycystic kidney disease identifies HNF4alpha as a disease modifier.
PLoS Genet. 8: e1003053, 2012.
79)  Johnson CH, Slanar O, Krausz KW, Kang DW, Patterson AD, Kim JH, Luecke H, Gonzalez FJ, Idle JR.
Novel metabolites and roles for alpha-tocopherol in humans and mice discovered by mass spectrometry-based metabolomics.
Am. J. Clin. Nutr. 96: 818-830, 2012.
80)  Gonzalez FJ.
Nuclear receptor control of enterohepatic circulation.
Compr Physiol. 2: 2811-28, 2012.
81)  Zhu B, Khozoie C, Bility MT, Ferry CH, Blazanin N, Glick AB, Gonzalez FJ, Peters JM.
Peroxisome proliferator-activated receptor beta/delta cross talks with E2F and attenuates mitosis in HRAS-expressing cells.
Mol. Cell. Biol. 32: 2065-82, 2012.
82)  Rosell M, Hondares E, Iwamoto S, Gonzalez FJ, Wabitsch M, Staels B, Olmos Y, Monsalve M, Giralt M, Iglesias R, Villarroya F.
Peroxisome proliferator-activated receptors-alpha and gamma, and cAMP-mediated pathways, control retinol-binding protein-4 gene expression in brown adipose tissue.
Endocrinology. 153: 1162-73, 2012.
83)  Ito Y, Nakamura T, Yanagiba Y, Ramdhan DH, Yamagishi N, Naito H, Kamijima M, Gonzalez FJ, Nakajima T.
Plasticizers may activatehuman hepatic peroxisome proliferator-activated receptor 1alpha Less than that of a mouse but may activate constitutive androstane receptor in liver.
PPAR Res. 2012: 201284, 2012.
84)  Patterson AD, Shah YM, Matsubara T, Krausz KW, Gonzalez FJ.
PPARalpha-dependent induction of uncoupling protein 2 protects against acetaminophen-induced liver toxicity.
Hepatology. 56: 281-90, 2012.
85)  Cheng J, Shah YM, Gonzalez FJ.
Pregnane X receptor as a target for treatment of inflammatory bowel disorders.
Trends Pharmacol Sci. 33: 323-30, 2012.
86)  Johnson CH, Patterson AD, Krausz KW, Kalinich JF, Tyburski JB, Kang DW, Luecke H, Gonzalez FJ, Blakely WF, Idle JR.
Radiation metabolomics. 5. Identification of urinary biomarkers of ionizing radiation exposure in nonhuman primates by mass spectrometry-based metabolomics.
Radiat. Res. 178: 328-40, 2012.
87)  Tanaka N, Gonzalez FJ.
Hepatology. 56: 2009, 2012.
88)  Skelhorne-Gross G, Reid AL, Apostoli AJ, Di Lena MA, Rubino RE, Peterson NT, Schneider M, SenGupta SK, Gonzalez FJ, Nicol CJ.
Stromal adipocyte PPARgamma protects against breast tumorigenesis.
Carcinogenesis. 33: 1412-20, 2012.
89)  Bonzo JA, Ferry CH, Matsubara T, Kim J, Gonzalez FJ.
Suppression of hepatocyte proliferation by hepatocyte nuclear factor 4alpha in adult mice.
J Biol Chem. 287: 7345-56, 2012.
90)  Matsubara T, Tanaka N, Sato M, Kang DW, Krausz KW, Flanders KC, Ikeda K, Luecke H, Wakefield LM, Gonzalez FJ.
TGF-beta-SMAD3 signaling mediates hepatic bile acid and phospholipid metabolism following lithocholic acid-induced liver injury.
J. Lipid Res. 53: 2698-707, 2012.
91)  Peters JM, Shah YM, Gonzalez FJ.
The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention.
Nat. Rev. Cancer. 12: 181-95, 2012.
92)  Sarkar K, Rey S, Zhang X, Sebastian R, Marti GP, Fox-Talbot K, Cardona AV, Du J, Tan YS, Liu L, Lay F, Gonzalez FJ, Harmon JW, Semenza GL.
Tie2-dependent knockout of HIF-1 impairs burn wound vascularization and homing of bone marrow-derived angiogenic cells.
Cardiovasc. Res. 93: 162-9, 2012.
93)  Li F, Patterson AD, Höfer CC, Krausz KW, Gonzalez FJ, Idle JR.
A comprehensive understanding of thioTEPA metabolism in the mouse using UPLC-ESI-QTOFMS-based metabolomics.
Biochem. Pharmacol. 81: 1043-53, 2011.
94)  Patterson AD, Maurhofer O, Beyoglu D, Lanz C, Krausz KW, Pabst T, Gonzalez FJ, Dufour J, Idle JR.
Aberrant lipid metabolism in hepatocellular carcinoma revealed by plasma metabolomics and lipid profiling.
Cancer Res. 71: 6590-600, 2011.
95)  Li Y, Ramdhan DH, Naito H, Yamagishi N, Ito Y, Hayashi Y, Yanagiba Y, Okamura A, Tamada H, Gonzalez FJ, Nakajima T.
Ammonium perfluorooctanoate may cause testosterone reduction by adversely affecting testis in relation to PPARalpha.
Toxicol. Lett. 205: 265-72, 2011.
96)  Liu A, Yang J, Gonzalez FJ, Cheng GQ, Dai R.
Biphasic regulation of intracellular calcium by gemfibrozil contributes to inhibiting L6 myoblast differentiation: implications for clinical myotoxicity.
Chem. Res. Toxicol. 24: 229-37, 2011.
97)  Johnson CH, Gonzalez FJ.
Challenges and opportunities of metabolomics.
J. Cell. Physiol. 2011.
98)  Elizondo G, Rodríguez-Sosa M, Estrada-Muñiz E, Gonzalez FJ, Vega L.
Deletion of the aryl hydrocarbon receptor enhances the inflammatory response to Leishmania major infection.
Int. J. Biol. Sci. 7: 1220-9, 2011.
99)  Jiang C, Qu A, Matsubara T, Chanturiya T, Jou W, Gavrilova O, Shah YM, Gonzalez FJ.
Disruption of hypoxia-inducible factor 1 in adipocytes improves Insulin sensitivity and decreases adiposity in high-fat diet-fed mice.
Diabetes. 60: 2484-95, 2011.
100)  Peters JM, Foreman JE, Gonzalez FJ.
Dissecting the role of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) in colon, breast, and lung carcinogenesis.
Cancer Metastasis Rev. 30: 619-40, 2011.
101)  Zhang Y, Bonzo JA, Gonzalez FJ, Wang L.
Diurnal regulation of the early growth response 1 (Egr-1) protein expression by hepatocyte nuclear factor 4alpha (HNF4{alpha}) and small heterodimer partner (SHP) cross-talk in liver fibrosis.
J. Biol. Chem. 286: 29635-43, 2011.
102)  Jiang XL, Gonzalez FJ, Yu AM.
Drug-metabolizing enzyme, transporter, and nuclear receptor genetically modified mouse models.
Drug Metab. Rev. 43: 27-40, 2011.
103)  Baghdasaryan A, Claudel T, Gumhold J, Silbert D, Adorini L, Roda A, Vecchiotti S, Gonzalez FJ, Schoonjans K, Strazzabosco M, Fickert P, Trauner M.
Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2-/- (Abcb4-/-) mouse cholangiopathy model by promoting biliary HCO-3 output.
Hepatology. 54: 1303-12, 2011.
104)  Prawitt J, Abdelkarim M, Stroeve JH, Popescu I, Duez H, Velagapudi VR, Dumont J, Bouchaert E, van Dijk TH, Lucas A, Dorchies E, Daoudi M, Lestavel S, Gonzalez FJ, Oresic M, Cariou B, Kuipers F, Caron S, Staels B.
Farnesoid x receptor deficiency improves glucose homeostasis in mouse models of obesity.
Diabetes. 60: 1861-71, 2011.
105)  Chennamsetty I, Claudel T, Kostner KM, Baghdasaryan A, Kratky D, Levak-Frank S, Frank S, Gonzalez FJ, Trauner M, Kostner GM.
Farnesoid X receptor represses hepatic human APOA gene expression.
J. Clin. Invest. 121: 3724-34, 2011.
106)  Foreman JE, Chang WL, Palkar PS, Zhu B, Borland MG, Williams JL, Kramer LR, Clapper ML, Gonzalez FJ, Peters JM.
Functional characterization of peroxisome proliferator-activated receptor-beta/delta expression in colon cancer.
Molecular carcinogenesis. 50: 884-900, 2011.
107)  Lindemer BJ, Bongard RD, Hoffmann R, Baumgardt S, Gonzalez FJ, Merker MP.
Genetic evidence for NAD(P)H:quinone oxidoreductase 1 catalyzed quinone reduction on passage through the mouse pulmonary circulation.
American journal of physiology. Lung cellular and molecular physiology. 300: 773-80, 2011.
108)  Shen HW, Jiang XL, Gonzalez FJ, Yu AM.
Humanized transgenic mouse models for drug metabolism and pharmacokinetic research.
Curr. Drug Metab. 12: 997-1006, 2011.
109)  Huerta-Yepez S, Baay-Guzman GJ, Bebenek IG, Hernandez-Pando R, Vega MI, Chi L, Riedl M, Diaz-Sanchez D, Kleerup E, Tashkin DP, Gonzalez FJ, Bonavida B, Zeidler M, Hankinson O.
Hypoxia inducible factor promotes murine allergic airway inflammation and is increased in asthma and rhinitis.
Allergy. 66: 909-18, 2011.
110)  Zhang H, Zhang G, Gonzalez FJ, Park SM, Cai D.
Hypoxia-inducible factor directs POMC gene to mediate hypothalamic glucose sensing and energy balance regulation.
PLoS Biol. 9: e1001112, 2011.
111)  Taylor M, Qu A, Anderson ER, Matsubara T, Martin A, Gonzalez FJ, Shah YM.
Hypoxia-inducible factor-2alpha mediates the adaptive increase of intestinal ferroportin during iron deficiency in mice.
Gastroenterology. 140: 2044-55, 2011.
112)  Qu A, Taylor M, Xue X, Matsubara T, Metzger D, Chambon P, Gonzalez FJ, Shah YM.
Hypoxia-inducible transcription factor 2alpha promotes steatohepatitis through augmenting lipid accumulation, inflammation, and fibrosis.
Hepatology. 54: 472-83, 2011.
113)  Matsubara T, Tanaka N, Patterson AD, Cho JY, Krausz KW, Gonzalez FJ.
Lithocholic acid disrupts phospholipid and sphingolipid homeostasis leading to cholestasis in mice.
Hepatology. 53: 1282-93, 2011.
114)  Patterson AD, Bonzo JA, Li F, Krausz KW, Eichler GS, Aslam S, Tigno X, Weinstein JN, Hansen BC, Idle JR, Gonzalez FJ.
Metabolomics reveals attenuation of the SLC6A20 kidney transporter in nonhuman primate and mouse models of type 2 diabetes mellitus.
Journal of biological chemistry. 286: 19511-22, 2011.
115)  Nakagawa T, Ramdhan DH, Tanaka N, Naito H, Tamada H, Ito Y, Li Y, Hayashi Y, Yamagishi N, Yanagiba Y, Aoyama T, Gonzalez FJ, Nakajima T.
Modulation of ammonium perfluorooctanoate-induced hepatic damage by genetically different PPARalpha in mice.
Archives of toxicology. 86: 63-74, 2011.
116)  Abdelmegeed MA, Yoo S, Henderson LE, Gonzalez FJ, Woodcroft KJ, Song B.
PPARalpha expression protects male mice from high fat-induced nonalcoholic fatty liver.
Journal of nutrition. 141: 603-10, 2011.
117)  Nakagawa K, Tanaka N, Morita M, Sugioka A, Miyagawa S, Gonzalez FJ, Aoyama T.
PPARalpha is down-regulated following liver transplantation in mice.
Journal of hepatology. 56: 586-94, 2011.
118)  Cheng J, Ma X, Gonzalez FJ.
Pregnane X receptor- and CYP3A4-humanized mouse models and their applications.
Br. J. Pharmacol. 163: 461-8, 2011.
119)  Pang X, Cheng J, Krausz KW, Guo DA, Gonzalez FJ.
Pregnane X receptor-mediated induction of Cyp3a by black cohosh.
Xenobiotica. 41: 112-23, 2011.
120)  Takahashi K, Kamijo Y, Hora K, Hashimoto K, Higuchi M, Nakajima T, Ehara T, Shigematsu H, Gonzalez FJ, Aoyama T.
Pretreatment by low-dose fibrates protects against acute free fatty acid-induced renal tubule toxicity by counteracting PPARα deterioration.
Toxicol. Appl. Pharmacol. 252: 237-49, 2011.
121)  Johnson CH, Patterson AD, Krausz KW, Lanz C, Kang DW, Luecke H, Gonzalez FJ, Idle JR.
Radiation metabolomics. 4. UPLC-ESI-QTOFMS-Based metabolomics for urinary biomarker discovery in gamma-irradiated rats.
Radiat. Res. 175: 473-84, 2011.
122)  Borland MG, Khozoie C, Albrecht PP, Zhu B, Lee C, Lahoti TS, Gonzalez FJ, Peters JM.
Stable over-expression of PPARbeta/delta and PPARgamma to examine receptor signaling in human HaCaT keratinocytes.
Cellular signalling. 23: 2039-2050, 2011.
123)  Lau SM, Lin S, Stokes RA, Cheng K, Baldock PA, Enriquez RF, McLean M, Cheung NW, Sainsbury A, Gonzalez FJ, Herzog H, Gunton JE.
Synergistic effects of genetic beta cell dysfunction and maternal glucose intolerance on offspring metabolic phenotype in mice.
Diabetologia. 54: 910-21, 2011.
124)  Santangelo L, Marchetti A, Cicchini C, Conigliaro A, Conti B, Mancone C, Bonzo JA, Gonzalez FJ, Alonzi T, Amicone L, Tripodi M.
The stable repression of mesenchymal program is required for hepatocyte identity: a novel role for hepatocyte nuclear factor 4alpha.
Hepatology. 53: 2063-74, 2011.
125)  Hondares E, Iglesias R, Giralt A, Gonzalez FJ, Giralt M, Mampel T, Villarroya F.
Thermogenic activation induces FGF21 expression and release in brown adipose tissue.
J. Biol. Chem. 286: 12983-90, 2011.
126)  Boverhof DR, Chamberlain MP, Elcombe CR, Gonzalez FJ, Heflich RH, Hernández LG, Jacobs AC, Jacobson-Kram D, Luijten M, Maggi A, Manjanatha MG, Benthem JV, Gollapudi BB.
Transgenic animal models in toxicology: historical perspectives and future outlook.
Toxicological sciences. 121: 207-33, 2011.
127)  Manna SK, Patterson AD, Yang Q, Krausz KW, Idle JR, Fornace AJ, Gonzalez FJ.
UPLC-MS-based urine metabolomics reveals indole-3-lactic acid and phenyllactic acid as conserved biomarkers for alcohol-induced liver disease in the Ppara-null mouse model.
J. Proteome Res. 10: 4120-33, 2011.
128)  Peters J, Gonzalez FJ.
Why toxic equivalency factors are not suitable for perfluoroalkyl chemicals.
Chemical research in toxicology. 24: 1601-9, 2011.
129)  Johnson CH, Patterson AD, Idle JR, Gonzalez FJ.
Xenobiotic metabolomics: major impact on the metabolome.
Annual review of pharmacology and toxicology. 52: 37-56, 2011.
130)  Genovese S, Foreman JE, Borland MG, Epifano F, Gonzalez FJ, Curini M, Peters JM.
A natural propenoic acid derivative activates peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta).
Life Sciences. 86: 493-8, 2010.
131)  Lee JH, Wada T, Febbraio M, He J, Matsubara T, Lee MJ, Gonzalez FJ, Xie W.
A novel role for the dioxin receptor in fatty acid metabolism and hepatic steatosis.
Gastroenterology. 139: 653-63, 2010.
132)  Lu H, Gonzalez FJ, Klaassen C.
Alterations in hepatic mRNA expression of phase II enzymes and xenobiotic transporters after targeted disruption of hepatocyte nuclear factor 4 alpha.
Toxicological sciences. 118: 380-90, 2010.
133)  Niu S, Li F, Tan DX, Zhang L, Idle JR, Gonzalez FJ, Ma X.
Analysis of N1-acetyl-N2-formyl-5-methoxykynuramine/N1-acetyl-5-methoxy-kynuramine formation from melatonin in mice.
J. Pineal Res. 49: 106-14, 2010.
134)  Palkar PS, Borland MG, Naruhn S, Ferry CH, Lee C, Sk UH, Sharma AK, Amin S, Murray IA, Anderson CR, Perdew GH, Gonzalez FJ, Müller R, Peters JM.
Cellular and pharmacological selectivity of the peroxisome proliferator-activated receptor-beta/delta antagonist GSK3787.
Mol. Pharmacol. 78: 419-30, 2010.
135)  Zhu B, Bai R, Kennett MJ, Kang BH, Gonzalez FJ, Peters JM.
Chemoprevention of chemically induced skin tumorigenesis by ligand activation of peroxisome proliferator-activated receptor-beta/delta and inhibition of cyclooxygenase 2.
Mol. Cancer Ther. 9: 3267-77, 2010.
136)  Li F, Patterson AD, Höfer CC, Krausz KW, Gonzalez FJ, Idle JR.
Comparative metabolism of cyclophosphamide and ifosfamide in the mouse using UPLC-ESI-QTOFMS-based metabolomics.
Biochem. Pharmacol. 80: 1063-74, 2010.
137)  Wang T, Shah YM, Matsubara T, Zhen Y, Tanabe T, Nagano T, Fotso S, Krausz KW, Zabriskie TM, Idle JR, Gonzalez FJ.
Control of steroid 21-oic acid synthesis by peroxisome proliferator-activated receptor alpha and role of the hypothalamic-pituitary-adrenal axis.
Journal of biological chemistry. 285: 7670-85, 2010.
138)  Jennings BL, Sahan-Firat S, Estes AM, Das K, Farjana N, Fang XR, Gonzalez FJ, Malik KU.
Cytochrome P450 1B1 contributes to angiotensin II-induced hypertension and associated pathophysiology.
Hypertension. 56: 667-74, 2010.
139)  Wang XX, Jiang T, Shen Y, Caldas Y, Miyazaki-Anzai S, Santamaria H, Urbanek C, Solis N, Scherzer P, Lewis L, Gonzalez FJ, Adorini L, Pruzanski M, Kopp JB, Verlander JW, Levi M.
Diabetic nephropathy is accelerated by farnesoid X receptor deficiency and inhibited by farnesoid X receptor activation in a type 1 diabetes model.
Diabetes. 59: 2916-27, 2010.
140)  Ramdhan DH, Kamijima M, Wang D, Ito Y, Naito H, Yanagiba Y, Hayashi Y, Tanaka N, Aoyama T, Gonzalez FJ, Nakajima T.
Differential response to trichloroethylene-induced hepatosteatosis in wild-type and PPARalpha-humanized mice.
Environ. Health Perspect. 118: 1557-63, 2010.
141)  Palkar PS, Anderson CR, Ferry CH, Gonzalez FJ, Peters JM.
Effect of prenatal peroxisome proliferator-activated receptor alpha (PPARalpha) agonism on postnatal development.
Toxicology. 276: 79-84, 2010.
142)  Tanaka N, Zhang X, Sugiyama E, Kono H, Horiuchi A, Nakajima T, Kanbe H, Tanaka E, Gonzalez FJ, Aoyama T.
Eicosapentaenoic acid improves hepatic steatosis independent of PPARalpha activation through inhibition of SREBP-1 maturation in mice.
Biochemical pharmacology. 80: 1601-12, 2010.
143)  Hondares E, Rosell M, Gonzalez FJ, Giralt M, Iglesias R, Villarroya F.
Hepatic FGF21 expression is induced at birth via PPARalpha in response to milk intake and contributes to thermogenic activation of neonatal brown fat.
Cell Metab. 11: 206-12, 2010.
144)  Martinez-Jimenez CP, Kyrmizi I, Cardot P, Gonzalez FJ, Talianidis I.
Hepatocyte nuclear factor 4alpha coordinates a transcription factor network regulating hepatic fatty acid metabolism.
Mol. Cell. Biol. 30: 565-77, 2010.
145)  Akita N, Tsujita M, Yokota T, Gonzalez FJ, Ohte N, Kimura G, Yokoyama S.
High Density Lipoprotein Turnover is Dependent on Peroxisome Proliferator-Activated Receptor alpha in Mice.
Journal of atherosclerosis and thrombosis. 17: 1149-59, 2010.
146)  Cheng K, Ho K, Stokes R, Scott C, Lau SM, Hawthorne WJ, O'Connell PJ, Loudovaris T, Kay TW, Kulkarni RN, Okada T, Wang XL, Yim SH, Shah Y, Grey ST, Biankin AV, Kench JG, Laybutt DR, Gonzalez FJ, Kahn CR, Gunton JE.
Hypoxia-inducible factor-1alpha regulates beta cell function in mouse and human islets.
J. Clin. Invest. 120: 2171-83, 2010.
147)  Manna SK, Patterson AD, Yang Q, Krausz KW, Li H, Idle JR, Fornace AJ, Gonzalez FJ.
Identification of noninvasive biomarkers for alcohol-induced liver disease usingurinary metabolomics and the Ppara-null mouse.
J. Proteome Res. 9: 4176-88, 2010.
148)  Zhang Y, Yin L, Anderson J, Ma H, Gonzalez FJ, Willson TM, Edwards PA.
Identification of novel pathways that control farnesoid X receptor-mediated hypocholesterolemia.
J. Biol. Chem. 285: 3035-43, 2010.
149)  Stroeve JH, Brufau G, Stellaard F, Gonzalez FJ, Staels B, Kuipers F.
Intestinal FXR-mediated FGF15 production contributes to diurnal control of hepatic bile acid synthesis in mice.
Laboratory investigation. 90: 1457-67, 2010.
150)  Bility MT, Zhu B, Kang BH, Gonzalez FJ, Peters JM.
Ligand activation of peroxisome proliferator-activated receptor-beta/delta and inhibition of cyclooxygenase-2 enhances inhibition of skin tumorigenesis.
Toxicol. Sci. 113: 27-36, 2010.
151)  Didon L, Roos AB, Elmberger GP, Gonzalez FJ, Nord M.
Lung-specific inactivation of CCAAT/enhancer binding protein alpha causes a pathological pattern characteristic of COPD.
Eur. Respir. J. 35: 186-97, 2010.
152)  Bonzo JA, Patterson AD, Krausz KW, Gonzalez FJ.
Metabolomics identifies novel Hnf1alpha-dependent physiological pathways in vivo.
Mol. Endocrinol. 24: 2343-55, 2010.
153)  Shi Z, Dragin N, Miller ML, Stringer KF, Johansson E, Chen J, Uno S, Gonzalez FJ, Rubio CA, Nebert DW.
Oral benzo[a]pyrene-induced cancer: two distinct types in different target organs depend on the mouse Cyp1 genotype.
Int. J. Cancer. 127: 2334-50, 2010.
154)  Qu A, Shah YM, Matsubara T, Yang Q, Gonzalez FJ.
PPARalpha-dependent activation of cell cycle control and DNA repair genes in hepatic non-parenchymal cells.
Toxicological sciences. 118: 404-10, 2010.
155)  Abdelmegeed MA, Moon K, Chen C, Gonzalez FJ, Song B.
Role of cytochrome P450 2E1 in protein nitration and ubiquitin-mediated degradation during acetaminophen toxicity.
Biochemical pharmacology. 79: 57-66, 2010.
156)  Kurobe H, Urata M, Ueno M, Ueki M, Ono S, Izawa-Ishizawa Y, Fukuhara Y, Lei Y, Ripen AM, Kanbara T, Aihara K, Ishizawa K, Akaike M, Gonzalez FJ, Tamaki T, Takahama Y, Yoshizumi M, Kitagawa T, Tomita S.
Role of hypoxia-inducible factor 1alpha in T cells as a negative regulator in development of vascular remodeling.
Arterioscler. Thromb. Vasc. Biol. 30: 210-7, 2010.
157)  Minata M, Harada KH, Kärrman A, Hitomi T, Hirosawa M, Murata M, Gonzalez FJ, Koizumi A.
Role of peroxisome proliferator-activated receptor-alpha in hepatobiliary injury induced by ammonium perfluorooctanoate in mouse liver.
Ind Health. 48: 96-107, 2010.
158)  Swanson HI, Njar VC, Yu Z, Castro DJ, Gonzalez FJ, Williams DE, Huang Y, Kong AN, Doloff JC, Ma J, Waxman DJ, Scott EE.
Targeting drug-metabolizing enzymes for effective chemoprevention and chemotherapy.
Drug Metab. Dispos. 38: 539-44, 2010.
159)  Chamouton J, Hansmannel F, Bonzo JA, Clémencet MC, Chevillard G, Battle M, Martin P, Pineau T, Duncan S, Gonzalez FJ, Latruffe N, Mandard S, Nicolas-Francès V.
The peroxisomal 3-keto-acyl-CoA thiolase B gene expression iIs under the dual control of PPARalpha and HNF4alpha in the liver.
PPAR Res. 2010: 352957, 2010.
160)  Feige JN, Gerber A, Casals-Casas C, Yang Q, Winkler C, Bedu E, Bueno M, Gelman L, Auwerx J, Gonzalez FJ, Desvergne B.
The pollutant diethylhexyl phthalate regulates hepatic energy metabolism via species-specific PPARalpha-dependent mechanisms.
Environ. Health Perspect. 118: 234-41, 2010.
161)  Cheng J, Shah YM, Ma X, Pang X, Tanaka T, Kodama T, Krausz KW, Gonzalez FJ.
Therapeutic role of rifaximin in inflammatory bowel disease: clinical implication of human pregnane X receptor activation.
J. Pharmacol. Exp. Ther. 335: 32-41, 2010.
162)  Reyes-Hernández OD, Mejía-García A, Sánchez-Ocampo EM, Cabañas-Cortés MA, Ramírez P, Chávez-González L, Gonzalez FJ, Elizondo G.
Ube2l3 gene expression is modulated by activation of the aryl hydrocarbon receptor: Implications for p53 ubiquitination.
Biochem. Pharmacol. 80: 932-40, 2010.
163)  Cho JY, Matsubara T, Kang DW, Ahn SH, Krausz KW, Idle JR, Luecke H, Gonzalez FJ.
Urinary metabolomics in Fxr-null mice reveals activated adaptive metabolic pathways upon bile acid challenge.
J. Lipid Res. 51: 1063-74, 2010.
164)  Patterson AD, Gonzalez FJ, Idle JR.
Xenobiotic metabolism: a view through the metabolometer.
Chem. Res. Toxicol. 23: 851-60, 2010.
165)  Guettier JM, Gautam D, Scarselli M, Ruiz de Azua I, Li JH, Rosemond E, Ma X, Gonzalez FJ, Armbruster BN, Lu H, Roth BL, Wess J.
A chemical-genetic approach to study G protein regulation of beta cell function in vivo.
Proc. Natl. Acad. Sci. U.S.A. 106: 19197-202, 2009.
166)  Wang XL, Suzuki R, Lee K, Tran T, Gunton JE, Saha AK, Patti ME, Goldfine A, Ruderman NB, Gonzalez FJ, Kahn CR.
Ablation of ARNT/HIF1beta in liver alters gluconeogenesis, lipogenic gene expression, and serum ketones.
Cell Metab. 9: 428-39, 2009.
167)  Nakajima T, Tanaka N, Kanbe H, Hara A, Kamijo Y, Zhang X, Gonzalez FJ, Aoyama T.
Bezafibrate at clinically relevant doses decreases serum/liver triglycerides via down-regulation of sterol regulatory element-binding protein-1c in mice: a novel peroxisome proliferator-activated receptor alpha-independent mechanism.
Mol. Pharmacol. 75: 782-92, 2009.
168)  Nomoto M, Miyata M, Yin S, Kurata Y, Shimada M, Yoshinari K, Gonzalez FJ, Suzuki K, Shibasaki S, Kurosawa T, Yamazoe Y.
Bile acid-induced elevated oxidative stress in the absence of farnesoid X receptor.
Biol. Pharm. Bull. 32: 172-8, 2009.
169)  Miyata M, Matsuda Y, Nomoto M, Takamatsu Y, Sato N, Hamatsu M, Dawson PA, Gonzalez FJ, Yamazoe Y.
Cholesterol feeding prevents hepatic accumulation of bile acids in cholic acid-fed farnesoid X receptor (FXR)-null mice: FXR-independent suppression of intestinal bile acid absorption.
Drug Metab. Dispos. 37: 338-44, 2009.
170)  Zhu JH, McClung JP, Zhang X, Aregullin M, Chen C, Gonzalez FJ, Kim TW, Lei XG.
Comparative impacts of knockouts of two antioxidant enzymes on acetaminophen-induced hepatotoxicity in mice.
Exp. Biol. Med. (Maywood). 234: 1477-83, 2009.
171)  Li L, Oropeza CE, Sainz B, Uprichard SL, Gonzalez FJ, McLachlan A.
Developmental regulation of hepatitis B virus biosynthesis by hepatocyte nuclear factor 4alpha.
PLoS ONE. 4: e5489, 2009.
172)  Foreman JE, Chang S, Ehresman DJ, Butenhoff JL, Anderson CR, Palkar PS, Kang B, Gonzalez FJ, Peters JM.
Differential hepatic effects of perfluorobutyrate mediated by mouse and human PPAR-alpha.
Toxicological sciences. 110: 204-11, 2009.
173)  Wang N, Symons JD, Zhang H, Jia Z, Gonzalez FJ, Yang T.
Distinct functions of vascular endothelial and smooth muscle PPARgamma in regulation of blood pressure and vascular tone.
Toxicologic pathology. 37: 21-7, 2009.
174)  Maran RR, Thomas A, Roth M, Sheng Z, Esterly N, Pinson D, Gao X, Zhang Y, Ganapathy V, Gonzalez FJ, Guo GL.
Farnesoid X receptor deficiency in mice leads to increased intestinal epithelial cell proliferation and tumor development.
J. Pharmacol. Exp. Ther. 328: 469-77, 2009.
175)  Liu A, Patterson AD, Yang Z, Zhang X, Liu W, Qiu F, Sun H, Krausz KW, Idle JR, Gonzalez FJ, Dai R.
Fenofibrate metabolism in the cynomolgus monkey using ultraperformance liquid chromatography-quadrupole time-of-flight mass spectrometry-based metabolomics.
Drug Metab. Dispos. 37: 1157-63, 2009.
176)  Cattin AL, Le Beyec J, Barreau F, Saint-Just S, Houllier A, Gonzalez FJ, Robine S, Pinçon-Raymond M, Cardot P, Lacasa M, Ribeiro A.
Hepatocyte nuclear factor 4alpha, a key factor for homeostasis, cell architecture, and barrier function of the adult intestinal epithelium.
Mol. Cell. Biol. 29: 6294-308, 2009.
177)  Patterson AD, Slanar O, Krausz KW, Li F, Höfer CC, Perlík F, Gonzalez FJ, Idle JR.
Human urinary metabolomic profile of PPARalpha induced fatty acid beta-oxidation.
J. Proteome Res. 8: 4293-300, 2009.
178)  Sekine H, Mimura J, Oshima M, Okawa H, Kanno J, Igarashi K, Gonzalez FJ, Ikuta T, Kawajiri K, Fujii-Kuriyama Y.
Hypersensitivity of aryl hydrocarbon receptor-deficient mice to lipopolysaccharide-induced septic shock.
Mol. Cell. Biol. 29: 6391-400, 2009.
179)  Ichihara S, Yamada Y, Gonzalez FJ, Nakajima T, Murohara T, Ichihara G.
Inhibition of ischemia-induced angiogenesis by benzo[a]pyrene in a manner dependent on the aryl hydrocarbon receptor.
Biochem. Biophys. Res. Commun. 381: 44-9, 2009.
180)  Shah YM, Matsubara T, Ito S, Yim S, Gonzalez FJ.
Intestinal hypoxia-inducible transcription factors are essential for iron absorption following iron deficiency.
Cell metabolism. 9: 152-64, 2009.
181)  Foreman JE, Sharma AK, Amin S, Gonzalez FJ, Peters JM.
Ligand activation of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) inhibits cell growth in a mouse mammary gland cancer cell line.
Cancer Lett. 2009.
182)  Cho JY, Kang DW, Ma X, Ahn SH, Krausz KW, Luecke H, Idle JR, Gonzalez FJ.
Metabolomics reveals a novel vitamin E metabolite and attenuated vitamin E metabolism upon PXR activation.
J. Lipid Res. 50: 924-37, 2009.
183)  Nakamura T, Ito Y, Yanagiba Y, Ramdhan DH, Kono Y, Naito H, Hayashi Y, Li Y, Aoyama T, Gonzalez FJ, Nakajima T.
Microgram-order ammonium perfluorooctanoate may activate mouse peroxisome proliferator-activated receptor alpha, but not human PPARalpha.
Toxicology. 265: 27-33, 2009.
184)  Liu A, Xie S, Sun H, Gonzalez FJ, Wei X, Dai R.
Myotoxicity of gemfibrozil in cynomolgus monkey model and its relationship to pharmacokinetic properties.
Toxicol. Appl. Pharmacol. 235: 287-95, 2009.
185)  Liu A, Chen Y, Yang Z, Feng Y, Rui W, Luo W, Liu Y, Gonzalez FJ, Dai R.
New metabolites of fenofibrate in Sprague-Dawley rats by UPLC-ESI-QTOF-MS-based metabolomics coupled with LC-MS/MS.
Xenobiotica. 39: 345-54, 2009.
186)  Yanagiba Y, Ito Y, Kamijima M, Gonzalez FJ, Nakajima T.
Octachlorostyrene induces cytochrome P450, UDP-glucuronosyltransferase and sulfotransferase via the aryl hydrocarbon receptor and constitutive androstane receptor.
Toxicological sciences. 111: 19-26, 2009.
187)  Ogata M, Tsujita M, Hossain MA, Akita N, Gonzalez FJ, Staels B, Suzuki S, Fukutomi T, Kimura G, Yokoyama S.
On the mechanism for PPAR agonists to enhance ABCA1 gene expression.
Atherosclerosis. 205: 413-9, 2009.
188)  Okiyama W, Tanaka N, Nakajima T, Tanaka E, Kiyosawa K, Gonzalez FJ, Aoyama T.
Polyenephosphatidylcholine prevents alcoholic liver disease in PPARalpha-null mice through attenuation of increases in oxidative stress.
J. Hepatol. 50: 1236-46, 2009.
189)  Kono K, Kamijo Y, Hora K, Takahashi K, Higuchi M, Kiyosawa K, Shigematsu H, Gonzalez FJ, Aoyama T.
PPAR{alpha} attenuates the proinflammatory response in activated mesangial cells.
Am. J. Physiol. Renal Physiol. 296: F328-36, 2009.
190)  Kanda T, Brown JD, Orasanu G, Vogel S, Gonzalez FJ, Sartoretto J, Michel T, Plutzky J.
PPARgamma in the endothelium regulates metabolic responses to high-fat diet in mice.
J. Clin. Invest. 119: 110-24, 2009.
191)  Tyburski JB, Patterson AD, Krausz KW, Slavík J, Fornace AJ, Gonzalez FJ, Idle JR.
Radiation metabolomics. 2. Dose- and time-dependent urinary excretion of deaminated purines and pyrimidines after sublethal gamma-radiation exposure in mice.
Radiat. Res. 172: 42-57, 2009.
192)  Lanz C, Patterson AD, Slavík J, Krausz KW, Ledermann M, Gonzalez FJ, Idle JR.
Radiation metabolomics. 3. Biomarker discovery in the urine of gamma-irradiated rats using a simplified metabolomics protocol of gas chromatography-mass spectrometry combined with random forests machine learning algorithm.
Radiat. Res. 172: 198-212, 2009.
193)  Moon JO, Welch TP, Gonzalez FJ, Copple BL.
Reduced liver fibrosis in hypoxia-inducible factor-1alpha-deficient mice.
Am. J. Physiol. Gastrointest. Liver Physiol. 296: G582-92, 2009.
194)  Foreman JE, Sorg JM, McGinnis KS, Rigas B, Williams JL, Clapper ML, Gonzalez FJ, Peters JM.
Regulation of peroxisome proliferator-activated receptor-beta/delta by the APC/beta-CATENIN pathway and nonsteroidal antiinflammatory drugs.
Mol. Carcinog. 48: 942-52, 2009.
195)  Elizondo G, Medina-Díaz IM, Cruz R, Gonzalez FJ, Vega L.
Retinoic acid modulates retinaldehyde dehydrogenase 1 gene expression through the induction of GADD153-C/EBPbeta interaction.
Biochem. Pharmacol. 77: 248-57, 2009.
196)  Cheng J, Ma X, Krausz KW, Idle JR, Gonzalez FJ.
Rifampicin-Activated Human PXR and CYP3A4 Induction Enhance Acetaminophen-Induced Toxicity.
Drug Metab. Dispos. 37: 1611-21, 2009.
197)  Abdelmegeed MA, Moon K, Hardwick JP, Gonzalez FJ, Song B.
Role of peroxisome proliferator-activated receptor-alpha in fasting-mediated oxidative stress.
Free Radic. Biol. Med. 47: 767-78, 2009.
198)  Chen C, Krausz KW, Shah YM, Idle JR, Gonzalez FJ.
Serum metabolomics reveals irreversible inhibition of fatty acid beta-oxidation through the suppression of PPARalpha activation as a contributing mechanism of acetaminophen-induced hepatotoxicity.
Chem. Res. Toxicol. 22: 699-707, 2009.
199)  Peters JM, Gonzalez FJ.
Sorting out the functional role(s) of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) in cell proliferation and cancer.
Biochim. Biophys. Acta. 1796: 230-41, 2009.
200)  Shi S, Yoon DY, Hodge-Bell KC, Bebenek IG, Whitekus MJ, Zhang R, Cochran AJ, Huerta-Yepez S, Yim SH, Gonzalez FJ, Jaiswal AK, Hankinson O.
The aryl hydrocarbon receptor nuclear translocator (Arnt) is required for tumor initiation by benzo[a]pyrene.
Carcinogenesis. 30: 1957-61, 2009.
201)  Wang XX, Jiang T, Shen Y, Adorini L, Pruzanski M, Gonzalez FJ, Scherzer P, Lewis L, Miyazaki-Anzai S, Levi M.
The farnesoid X receptor modulates renal lipid metabolism and diet-induced renal inflammation, fibrosis, and proteinuria.
Am. J. Physiol. Renal Physiol. 297: F1587-96, 2009.
202)  Patterson AD, Lanz C, Gonzalez FJ, Idle JR.
The role of mass spectrometry-based metabolomics in medical countermeasures against radiation.
Mass Spectrom Rev. 29: 503-21, 2009.
203)  Ma X, Cheung C, Krausz KW, Shah YM, Wang T, Idle JR, Gonzalez FJ.
A double transgenic mouse model expressing human pregnane X receptor and cytochrome P450 3A4.
Drug Metab. Dispos. 36: 2506-12, 2008.
204)  He P, Borland MG, Zhu B, Sharma AK, Amin S, El-Bayoumy K, Gonzalez FJ, Peters JM.
Effect of ligand activation of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) in human lung cancer cell lines.
Toxicology. 254: 112-7, 2008.
205)  Castro DJ, Baird WM, Pereira CB, Giovanini J, Löhr CV, Fischer KA, Yu Z, Gonzalez FJ, Krueger SK, Williams DE.
Fetal mouse Cyp1b1 and transplacental carcinogenesis from maternal exposure to dibenzo(a,l)pyrene.
Cancer prevention research. 1: 128-34, 2008.
206)  Cheung C, Gonzalez FJ.
Humanized mouse lines and their application for prediction of human drug metabolism and toxicological risk assessment.
J. Pharmacol. Exp. Ther. 327: 288-99, 2008.
207)  Bility MT, Devlin-Durante MK, Blazanin N, Glick AB, Ward JM, Kang BH, Kennett MJ, Gonzalez FJ, Peters JM.
Ligand activation of peroxisome proliferator-activated receptor beta/delta (PPAR beta/delta) inhibits chemically induced skin tumorigenesis.
Carcinogenesis. 29: 2406-14, 2008.
208)  Shan W, Palkar PS, Murray IA, McDevitt EI, Kennett MJ, Kang BH, Isom HC, Perdew GH, Gonzalez FJ, Peters JM.
Ligand activation of peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) attenuates carbon tetrachloride hepatotoxicity by downregulating proinflammatory gene expression.
Toxicological sciences. 105: 418-28, 2008.
209)  Borland MG, Foreman JE, Girroir EE, Zolfaghari R, Sharma AK, Amin S, Gonzalez FJ, Ross AC, Peters JM.
Ligand activation of peroxisome proliferator-activated receptor-beta/delta inhibits cell proliferation in human HaCaT keratinocytes.
Mol. Pharmacol. 74: 1429-42, 2008.
210)  Ramdhan DH, Kamijima M, Yamada N, Ito Y, Yanagiba Y, Nakamura D, Okamura A, Ichihara G, Aoyama T, Gonzalez FJ, Nakajima T.
Molecular mechanism of trichloroethylene-induced hepatotoxicity mediated by CYP2E1.
Toxicol. Appl. Pharmacol. 231: 300-7, 2008.
211)  Girroir EE, Hollingshead HE, Billin AN, Willson TM, Robertson GP, Sharma AK, Amin S, Gonzalez FJ, Peters JM.
Peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) ligands inhibit growth of UACC903 and MCF7 human cancer cell lines.
Toxicology. 243: 236-43, 2008.
212)  Gonzalez FJ.
Regulation of hepatocyte nuclear factor 4alpha-mediated transcription.
Drug Metab. Pharmacokinet. 23: 2-7, 2008.
213)  Minami K, Nakajima M, Fujiki Y, Katoh M, Gonzalez FJ, Yokoi T.
Regulation of insulin-like growth factor binding protein-1 and lipoprotein lipase by the aryl hydrocarbon receptor.
The Journal of toxicological sciences. 33: 405-13, 2008.
214)  Jennewein C, Kuhn AM, Schmidt MV, Meilladec-Jullig V, von Knethen A, Gonzalez FJ, Brüne B.
Sumoylation of peroxisome proliferator-activated receptor gamma by apoptotic cells prevents lipopolysaccharide-induced NCoR removal from kappaB binding sites mediating transrepression of proinflammatory cytokines.
J. Immunol. 181: 5646-52, 2008.
215)  Yang Q, Nagano T, Shah Y, Cheung C, Ito S, Gonzalez FJ.
The PPAR alpha-humanized mouse: a model to investigate species differences in liver toxicity mediated by PPAR alpha.
Toxicol. Sci. 101: 132-9, 2008.
216)  Patterson AD, Li H, Eichler GS, Krausz KW, Weinstein JN, Fornace AJ, Gonzalez FJ, Idle JR.
UPLC-ESI-TOFMS-based metabolomics and gene expression dynamics inspector self-organizing metabolomic maps as tools for understanding the cellular response to ionizing radiation.
Anal. Chem. 80: 665-74, 2008.
217)  Wang N, Yang G, Jia Z, Zhang H, Aoyagi T, Soodvilai S, Symons JD, Schnermann JB, Gonzalez FJ, Litwin SE, Yang T.
Vascular PPARgamma controls circadian variation in blood pressure and heart rate through Bmal1.
Cell Metab. 8: 482-91, 2008.
218)  Naito H, Kamijima M, Yamanoshita O, Nakahara A, Katoh T, Tanaka N, Aoyama T, Gonzalez FJ, Nakajima T.
Differential effects of aging, drinking and exercise on serum cholesterol levels dependent on the PPARA-V227A polymorphism.
Journal of occupational health. 49: 353-62, 2007.
219)  Nomoto M, Miyata M, Shimada M, Yoshinari K, Gonzalez FJ, Shibasaki S, Kurosawa T, Shindo Y, Yamazoe Y.
ME3738 protects against lithocholic acid-induced hepatotoxicity, which is associated with enhancement of biliary bile acid and cholesterol output.
Eur. J. Pharmacol. 574: 192-200, 2007.
220)  Zhen Y, Krausz KW, Chen C, Idle JR, Gonzalez FJ.
Metabolomic and genetic analysis of biomarkers for peroxisome proliferator-activated receptor alpha expression and activation.
Mol. Endocrinol. 21: 2136-51, 2007.
221)  Hollingshead HE, Morimura K, Adachi M, Kennett MJ, Billin AN, Willson TM, Gonzalez FJ, Peters JM.
PPARbeta/delta protects against experimental colitis through a ligand-independent mechanism.
Dig. Dis. Sci. 52: 2912-9, 2007.
222)  Lee CH, Ito Y, Yanagiba Y, Yamanoshita O, Kim H, Zhang SY, Kamijima M, Gonzalez FJ, Nakajima T.
Pyrene-induced CYP1A2 and SULT1A1 may be regulated by CAR and not by AhR.
Toxicology. 238: 147-56, 2007.
223)  Kim DJ, Prabhu KS, Gonzalez FJ, Peters JM.
Inhibition of chemically induced skin carcinogenesis by sulindac is independent of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta).
Carcinogenesis. 27: 1105-12, 2006.
224)  Kim DJ, Bility MT, Billin AN, Willson TM, Gonzalez FJ, Peters JM.
PPARbeta/delta selectively induces differentiation and inhibits cell proliferation.
Cell Death Differ. 13: 53-60, 2006.
225)  Shin M, Kim I, Inoue Y, Kimura S, Gonzalez FJ.
Regulation of mouse hepatic alpha-amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase, a key enzyme in the tryptophan-nicotinamide adenine dinucleotide pathway, by hepatocyte nuclear factor 4alpha and peroxisome proliferator-activated receptor alpha.
Mol. Pharmacol. 70: 1281-90, 2006.
226)  Burdick AD, Kim DJ, Peraza MA, Gonzalez FJ, Peters JM.
The role of peroxisome proliferator-activated receptor-beta/delta in epithelial cell growth and differentiation.
Cell. Signal. 18: 9-20, 2006.
227)  Murray IA, Reen RK, Leathery N, Ramadoss P, Bonati L, Gonzalez FJ, Peters JM, Perdew GH.
Evidence that ligand binding is a key determinant of Ah receptor-mediated transcriptional activity.
Arch. Biochem. Biophys. 442: 59-71, 2005.
228)  Miksys SL, Cheung C, Gonzalez FJ, Tyndale RF.
Human CYP2D6 and mouse CYP2Ds: organ distribution in a humanized mouse model.
Drug Metab. Dispos. 33: 1495-502, 2005.
229)  Peters JM, Cheung C, Gonzalez FJ.
Peroxisome proliferator-activated receptor-alpha and liver cancer: where do we stand?.
J. Mol. Med. 83: 774-85, 2005.
230)  Inoue Y, Inoue J, Lambert G, Yim SH, Gonzalez FJ.
Disruption of hepatic C/EBPalpha results in impaired glucose tolerance and age-dependent hepatosteatosis.
Journal of biological chemistry. 279: 44740-8, 2004.
231)  Guo GL, Moffit JS, Nicol CJ, Ward JM, Aleksunes LA, Slitt AL, Kliewer SA, Manautou JE, Gonzalez FJ.
Enhanced acetaminophen toxicity by activation of the pregnane X receptor.
Toxicol. Sci. 82: 374-80, 2004.
232)  Zhang Y, Repa JJ, Inoue Y, Hayhurst GP, Gonzalez FJ, Mangelsdorf DJ.
Identification of a liver-specific uridine phosphorylase that is regulated by multiple lipid-sensing nuclear receptors.
Mol. Endocrinol. 18: 851-62, 2004.
233)  Yu AM, Idle JR, Gonzalez FJ.
Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates.
Drug Metab. Rev. 36: 243-77, 2004.
234)  Bondoc FY, Bao Z, Hu WY, Gonzalez FJ, Wang Y, Yang CS, Hong JY.
Acetone catabolism by cytochrome P450 2E1: studies with CYP2E1-null mice.
Biochem. Pharmacol. 58: 461-3, 1999.
235)  Peters JM, Narotsky MG, Elizondo G, Fernandez-Salguero PM, Gonzalez FJ, Abbott BD.
Amelioration of TCDD-induced teratogenesis in aryl hydrocarbon receptor (AhR)-null mice.
Toxicol. Sci. 47: 86-92, 1999.
236)  Sai Y, Yang TJ, Krausz KW, Gonzalez FJ, Gelboin HV.
An inhibitory monoclonal antibody to human cytochrome P450 2A6 defines its role in the metabolism of coumarin, 7-ethoxycoumarin and 4-nitroanisole in human liver.
Pharmacogenetics. 9: 229-37, 1999.
237)  Kimura S, Kawabe M, Ward JM, Morishima H, Kadlubar FF, Hammons GJ, Fernandez-Salguero P, Gonzalez FJ.
CYP1A2 is not the primary enzyme responsible for 4-aminobiphenyl-induced hepatocarcinogenesis in mice.
Carcinogenesis. 20: 1825-30, 1999.
238)  Buters JT, Sakai S, Richter T, Pineau T, Alexander DL, Savas U, Doehmer J, Ward JM, Jefcoate CR, Gonzalez FJ.
Cytochrome P450 CYP1B1 determines susceptibility to 7, 12-dimethylbenz[a]anthracene-induced lymphomas.
Proc. Natl. Acad. Sci. U.S.A. 96: 1977-82, 1999.
239)  Tracy TS, Korzekwa KR, Gonzalez FJ, Wainer IW.
Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil.
Br J Clin Pharmacol. 47: 545-52, 1999.
240)  Buters JT, Doehmer J, Gonzalez FJ.
Cytochrome P450-null mice.
Drug Metab. Rev. 31: 437-47, 1999.
241)  Hill MR, Clarke S, Rodgers K, Thornhill B, Peters JM, Gonzalez FJ, Gimble JM.
Effect of peroxisome proliferator-activated receptor alpha activators on tumor necrosis factor expression in mice during endotoxemia.
Infect. Immun. 67: 3488-93, 1999.
242)  Yang TJ, Krausz KW, Sai Y, Gonzalez FJ, Gelboin HV.
Eight inhibitory monoclonal antibodies define the role of individual P-450s in human liver microsomal diazepam, 7-ethoxycoumarin, and imipramine metabolism.
Drug Metab. Dispos. 27: 102-9, 1999.
243)  Kockx M, Gervois PP, Poulain P, Derudas B, Peters JM, Gonzalez FJ, Princen HM, Kooistra T, Staels B.
Fibrates suppress fibrinogen gene expression in rodents via activation of the peroxisome proliferator-activated receptor-alpha.
Blood. 93: 2991-8, 1999.
244)  Guidotti LG, Eggers CM, Raney AK, Chi SY, Peters JM, Gonzalez FJ, McLachlan A.
In vivo regulation of hepatitis B virus replication by peroxisome proliferators.
J. Virol. 73: 10377-86, 1999.
245)  Gelboin HV, Krausz KW, Gonzalez FJ, Yang TJ.
Inhibitory monoclonal antibodies to human cytochrome P450 enzymes: a new avenue for drug discovery.
Trends Pharmacol. Sci. 20: 432-8, 1999.
246)  Benito MP, Valderrama JE, González FJ, Muniáin JM.
Intestinal occlusion and spigelian hernia.
J. Clin. Gastroenterol. 29: 213-4, 1999.
247)  Hong JY, Wang YY, Bondoc FY, Yang CS, Gonzalez FJ, Pan Z, Cokonis CD, Hu WY, Bao Z.
Metabolism of methyl tert-butyl ether and other gasoline ethers in mouse liver microsomes lacking cytochrome P450 2E1.
Toxicol. Lett. 105: 83-8, 1999.
248)  Barclay TB, Peters JM, Sewer MB, Ferrari L, Gonzalez FJ, Morgan ET.
Modulation of cytochrome P-450 gene expression in endotoxemic mice is tissue specific and peroxisome proliferator-activated receptor-alpha dependent.
J. Pharmacol. Exp. Ther. 290: 1250-7, 1999.
249)  Hashimoto T, Fujita T, Usuda N, Cook W, Qi C, Peters JM, Gonzalez FJ, Yeldandi AV, Rao MS, Reddy JK.
Peroxisomal and mitochondrial fatty acid beta-oxidation in mice nullizygous for both peroxisome proliferator-activated receptor alpha and peroxisomal fatty acyl-CoA oxidase. Genotype correlation with fatty liver phenotype.
Journal of biological chemistry. 274: 19228-36, 1999.
250)  Kersten S, Seydoux J, Peters JM, Gonzalez FJ, Desvergne B, Wahli W.
Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting.
J. Clin. Invest. 103: 1489-98, 1999.
251)  Delerive P, De Bosscher K, Besnard S, Vanden Berghe W, Peters JM, Gonzalez FJ, Fruchart JC, Tedgui A, Haegeman G, Staels B.
Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1.
J. Biol. Chem. 274: 32048-54, 1999.
252)  Peters JM, Morishima H, Ward JM, Coakley CJ, Kimura S, Gonzalez FJ.
Role of CYP1A2 in the toxicity of long-term phenacetin feeding in mice.
Toxicol. Sci. 50: 82-9, 1999.
253)  Ghanayem BI, Sanders JM, Chanas B, Burka LT, Gonzalez FJ.
Role of cytochrome P-450 2E1 in methacrylonitrile metabolism and disposition.
J. Pharmacol. Exp. Ther. 289: 1054-9, 1999.
254)  Gonzalez FJ, Kimura S.
Role of gene knockout mice in understanding the mechanisms of chemical toxicity and carcinogenesis.
Cancer Lett. 143: 199-204, 1999.
255)  Lanza DL, Code E, Crespi CL, Gonzalez FJ, Yost GS.
Specific dehydrogenation of 3-methylindole and epoxidation of naphthalene by recombinant human CYP2F1 expressed in lymphoblastoid cells.
Drug Metab. Dispos. 27: 798-803, 1999.
256)  Nagata K, Ogino M, Shimada M, Miyata M, Gonzalez FJ, Yamazoe Y.
Structure and expression of the rat CYP3A1 gene: isolation of the gene (P450/6betaB) and characterization of the recombinant protein.
Arch. Biochem. Biophys. 362: 242-53, 1999.
257)  Miyata M, Kudo G, Lee YH, Yang TJ, Gelboin HV, Fernandez-Salguero P, Kimura S, Gonzalez FJ.
Targeted disruption of the microsomal epoxide hydrolase gene. Microsomal epoxide hydrolase is required for the carcinogenic activity of 7,12-dimethylbenz[a]anthracene.
Journal of biological chemistry. 274: 23963-8, 1999.
258)  Djouadi F, Brandt JM, Weinheimer CJ, Leone TC, Gonzalez FJ, Kelly DP.
The role of the peroxisome proliferator-activated receptor alpha (PPAR alpha) in the control of cardiac lipid metabolism.
Prostaglandins Leukot. Essent. Fatty Acids. 60: 339-43, 1999.
259)  Chen HJ, Gonzalez FJ, Shou M, Chung FL.
2,3-epoxy-4-hydroxynonanal, a potential lipid peroxidation product for etheno adduct formation, is not a substrate of human epoxide hydrolase.
Carcinogenesis. 19: 939-43, 1998.
260)  Djouadi F, Weinheimer CJ, Saffitz JE, Pitchford C, Bastin J, Gonzalez FJ, Kelly DP.
A gender-related defect in lipid metabolism and glucose homeostasis in peroxisome proliferator- activated receptor alpha- deficient mice.
J. Clin. Invest. 102: 1083-91, 1998.
261)  Aoyama T, Peters JM, Iritani N, Nakajima T, Furihata K, Hashimoto T, Gonzalez FJ.
Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor alpha (PPARalpha).
J. Biol. Chem. 273: 5678-84, 1998.
262)  Hansen AJ, Lee YH, Sterneck E, Gonzalez FJ, Mackenzie PI.
C/EBPalpha is a regulator of the UDP glucuronosyltransferase UGT2B1 gene.
Mol. Pharmacol. 53: 1027-33, 1998.
263)  Wei X, Elizondo G, Sapone A, McLeod HL, Raunio H, Fernandez-Salguero P, Gonzalez FJ.
Characterization of the human dihydropyrimidine dehydrogenase gene.
Genomics. 51: 391-400, 1998.
264)  Torres MJ, Gonzalez FJ, Corzo JL, Giron MD, Carvajal MJ, Garcia V, Pinedo A, Martinez-Valverde A, Blanca M, Santamaria LF.
Circulating CLA+ lymphocytes from children with atopic dermatitis contain an increased percentage of cells bearing staphylococcal-related T-cell receptor variable segments.
Clin. Exp. Allergy. 28: 1264-72, 1998.
265)  Ridge SA, Sludden J, Brown O, Robertson L, Wei X, Sapone A, Fernandez-Salguero PM, Gonzalez FJ, Vreken P, van Kuilenburg AB, van Gennip AH, McLeod HL.
Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects.
Br J Clin Pharmacol. 46: 151-6, 1998.
266)  Ridge SA, Sludden J, Wei X, Sapone A, Brown O, Hardy S, Canney P, Fernandez-Salguero P, Gonzalez FJ, Cassidy J, McLeod HL.
Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer.
Br. J. Cancer. 77: 497-500, 1998.
267)  Radjendirane V, Joseph P, Lee YH, Kimura S, Klein-Szanto AJ, Gonzalez FJ, Jaiswal AK.
Disruption of the DT diaphorase (NQO1) gene in mice leads to increased menadione toxicity.
J. Biol. Chem. 273: 7382-9, 1998.
268)  Zaher H, Yang TJ, Gelboin HV, Fernandez-Salguero P, Gonzalez FJ.
Effect of phenobarbital on hepatic CYP1A1 and CYP1A2 in the Ahr-null mouse.
Biochem. Pharmacol. 55: 235-8, 1998.
269)  Suzuki A, Kushida H, Iwata H, Watanabe M, Nohmi T, Fujita K, Gonzalez FJ, Kamataki T.
Establishment of a Salmonella tester strain highly sensitive to mutagenic heterocyclic amines.
Cancer Res. 58: 1833-8, 1998.
270)  Korzekwa KR, Krishnamachary N, Shou M, Ogai A, Parise RA, Rettie AE, Gonzalez FJ, Tracy TS.
Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites.
Biochemistry. 37: 4137-47, 1998.
271)  Motojima K, Passilly P, Peters JM, Gonzalez FJ, Latruffe N.
Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor alpha and gamma activators in a tissue- and inducer-specific manner.
J. Biol. Chem. 273: 16710-4, 1998.
272)  Yang TJ, Sai Y, Krausz KW, Gonzalez FJ, Gelboin HV.
Inhibitory monoclonal antibodies to human cytochrome P450 1A2: analysis of phenacetin O-deethylation in human liver.
Pharmacogenetics. 8: 375-82, 1998.
273)  Yang TJ, Krausz KW, Shou M, Yang SK, Buters JT, Gonzalez FJ, Gelboin HV.
Inhibitory monoclonal antibody to human cytochrome P450 2B6.
Biochem. Pharmacol. 55: 1633-40, 1998.
274)  Lee YH, Sauer B, Gonzalez FJ.
Laron dwarfism and non-insulin-dependent diabetes mellitus in the Hnf-1alpha knockout mouse.
Mol. Cell. Biol. 18: 3059-68, 1998.
275)  Saarikoski ST, Husgafvel-Pursiainen K, Hirvonen A, Vainio H, Gonzalez FJ, Anttila S.
Localization of CYP1A1 mRNA in human lung by in situ hybridization: comparison with immunohistochemical findings.
Int. J. Cancer. 77: 33-9, 1998.
276)  Gonzalez FJ, Peters JM, Cattley RC.
Mechanism of action of the nongenotoxic peroxisome proliferators: role of the peroxisome proliferator-activator receptor alpha.
J. Natl. Cancer Inst. 90: 1702-9, 1998.
277)  Yamamoto Y, Tasaki T, Nakamura A, Iwata H, Kazusaka A, Gonzalez FJ, Fujita S.
Molecular basis of the Dark Agouti rat drug oxidation polymorphism: importance of CYP2D1 and CYP2D2.
Pharmacogenetics. 8: 73-82, 1998.
278)  McLeod HL, Collie-Duguid ES, Vreken P, Johnson MR, Wei X, Sapone A, Diasio RB, Fernandez-Salguero P, van Kuilenberg AB, van Gennip AH, Gonzalez FJ.
Nomenclature for human DPYD alleles.
Pharmacogenetics. 8: 455-9, 1998.
279)  González FJ, Leyva L, Posadas S, Luque I, Blanca M, Santamaría L, Juarez C.
Participation of T lymphocytes in cutaneous allergic reactions to drugs.
Clin. Exp. Allergy. 28 Suppl 4: 3-6, 1998.
280)  Morgan ET, Sewer MB, Iber H, Gonzalez FJ, Lee YH, Tukey RH, Okino S, Vu T, Chen YH, Sidhu JS, Omiecinski CJ.
Physiological and pathophysiological regulation of cytochrome P450.
Drug Metab. Dispos. 26: 1232-40, 1998.
281)  Zaher H, Buters JT, Ward JM, Bruno MK, Lucas AM, Stern ST, Cohen SD, Gonzalez FJ.
Protection against acetaminophen toxicity in CYP1A2 and CYP2E1 double-null mice.
Toxicol. Appl. Pharmacol. 152: 193-9, 1998.
282)  Ward JM, Peters JM, Perella CM, Gonzalez FJ.
Receptor and nonreceptor-mediated organ-specific toxicity of di(2-ethylhexyl)phthalate (DEHP) in peroxisome proliferator-activated receptor alpha-null mice.
Toxicol Pathol. 26: 240-6, 1998.
283)  Yang TJ, Shou M, Korzekwa KR, Gonzalez FJ, Gelboin HV, Yang SK.
Role of cDNA-expressed human cytochromes P450 in the metabolism of diazepam.
Biochem. Pharmacol. 55: 889-96, 1998.
284)  Shou M, Martinet M, Korzekwa KR, Krausz KW, Gonzalez FJ, Gelboin HV.
Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: enzyme specificity, interindividual distribution and metabolic contribution in human liver.
Pharmacogenetics. 8: 391-401, 1998.
285)  Peters JM, Aoyama T, Cattley RC, Nobumitsu U, Hashimoto T, Gonzalez FJ.
Role of peroxisome proliferator-activated receptor alpha in altered cell cycle regulation in mouse liver.
Carcinogenesis. 19: 1989-94, 1998.
286)  Gonzalez FJ, Fernandez-Salguero P.
The aryl hydrocarbon receptor: studies using the AHR-null mice.
Drug Metab. Dispos. 26: 1194-8, 1998.
287)  Zaher H, Fernandez-Salguero PM, Letterio J, Sheikh MS, Fornace AJ, Roberts AB, Gonzalez FJ.
The involvement of aryl hydrocarbon receptor in the activation of transforming growth factor-beta and apoptosis.
Mol. Pharmacol. 54: 313-21, 1998.
288)  Gonzalez FJ.
The study of xenobiotic-metabolizing enzymes and their role in toxicity in vivo using targeted gene disruption.
Toxicol. Lett. 102-103: 161-6, 1998.
289)  Gelboin HV, Krausz KW, Shou M, Gonzalez FJ, Yang TJ.
A monoclonal antibody inhibitory to human P450 2D6: a paradigm for use in combinatorial determination of individual P450 role in specific drug tissue metabolism.
Pharmacogenetics. 7: 469-77, 1997.
290)  Macé K, Aguilar F, Wang JS, Vautravers P, Gómez-Lechón M, Gonzalez FJ, Groopman J, Harris CC, Pfeifer AM.
Aflatoxin B1-induced DNA adduct formation and p53 mutations in CYP450-expressing human liver cell lines.
Carcinogenesis. 18: 1291-7, 1997.
291)  Peters JM, Hennuyer N, Staels B, Fruchart JC, Fievet C, Gonzalez FJ, Auwerx J.
Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor alpha-deficient mice.
J. Biol. Chem. 272: 27307-12, 1997.
292)  Andreola F, Fernandez-Salguero PM, Chiantore MV, Petkovich MP, Gonzalez FJ, De Luca LM.
Aryl hydrocarbon receptor knockout mice (AHR-/-) exhibit liver retinoid accumulation and reduced retinoic acid metabolism.
Cancer Res. 57: 2835-8, 1997.
293)  Chen L, Buters JT, Hardwick JP, Tamura S, Penman BW, Gonzalez FJ, Crespi CL.
Coexpression of cytochrome P4502A6 and human NADPH-P450 oxidoreductase in the baculovirus system.
Drug Metab. Dispos. 25: 399-405, 1997.
294)  Peters JM, Taubeneck MW, Keen CL, Gonzalez FJ.
Di(2-ethylhexyl) phthalate induces a functional zinc deficiency during pregnancy and teratogenesis that is independent of peroxisome proliferator-activated receptor-alpha.
Teratology. 56: 311-6, 1997.
295)  Lee YH, Sauer B, Johnson PF, Gonzalez FJ.
Disruption of the c/ebp alpha gene in adult mouse liver.
Mol. Cell. Biol. 17: 6014-22, 1997.
296)  Gonzalez FJ, Carvajal MJ, del Pozo V, Lahoz C, Santamaria L, Blanca M, Juarez C.
Erythema multiforme to phenobarbital: involvement of eosinophils and T cells expressing the skin homing receptor.
J. Allergy Clin. Immunol. 100: 135-7, 1997.
297)  Gonzalez FJ, Carvajal MJ, Leiva L, Juarez C, Blanca M, Santamaria LF.
Expression of the cutaneous lymphocyte-associated antigen in circulating T cells in drug-allergic reactions.
Int. Arch. Allergy Immunol. 113: 345-7, 1997.
298)  Hansen AJ, Lee YH, Gonzalez FJ, Mackenzie PI.
HNF1 alpha activates the rat UDP glucuronosyltransferase UGT2B1 gene promoter.
DNA Cell Biol. 16: 207-14, 1997.
299)  Sadeque AJ, Fisher MB, Korzekwa KR, Gonzalez FJ, Rettie AE.
Human CYP2C9 and CYP2A6 mediate formation of the hepatotoxin 4-ene-valproic acid.
J. Pharmacol. Exp. Ther. 283: 698-703, 1997.
300)  Code EL, Crespi CL, Penman BW, Gonzalez FJ, Chang TK, Waxman DJ.
Human cytochrome P4502B6: interindividual hepatic expression, substrate specificity, and role in procarcinogen activation.
Drug Metab. Dispos. 25: 985-93, 1997.
301)  Krausz KW, Yang TJ, Gonzalez FJ, Shou M, Gelboin HV.
Inhibitory monoclonal antibodies to human cytochrome P450 2D6.
Biochemical pharmacology. 54: 15-7, 1997.
302)  Tracy TS, Marra C, Wrighton SA, Gonzalez FJ, Korzekwa KR.
Involvement of multiple cytochrome P450 isoforms in naproxen O-demethylation.
Eur. J. Clin. Pharmacol. 52: 293-8, 1997.
303)  Fernandez-Salguero PM, Sapone A, Wei X, Holt JR, Jones S, Idle JR, Gonzalez FJ.
Lack of correlation between phenotype and genotype for the polymorphically expressed dihydropyrimidine dehydrogenase in a family of Pakistani origin.
Pharmacogenetics. 7: 161-3, 1997.
304)  Fernandez-Salguero PM, Ward JM, Sundberg JP, Gonzalez FJ.
Lesions of aryl-hydrocarbon receptor-deficient mice.
Vet. Pathol. 34: 605-14, 1997.
305)  Ridge SA, Brown O, McMurrough J, Fernandez-Salguero P, Evans WE, Gonzalez FJ, McLeod HL.
Mutations at codon 974 of the DPYD gene are a rare event.
Br. J. Cancer. 75: 178-9, 1997.
306)  Gonzalez FJ.
Overview of experimental approaches for study of drug metabolism and drug-drug interactions.
Adv. Pharmacol. 43: 255-77, 1997.
307)  Ren B, Thelen AP, Peters JM, Gonzalez FJ, Jump DB.
Polyunsaturated fatty acid suppression of hepatic fatty acid synthase and S14 gene expression does not require peroxisome proliferator-activated receptor alpha.
J. Biol. Chem. 272: 26827-32, 1997.
308)  Motojima K, Peters JM, Gonzalez FJ.
PPAR alpha mediates peroxisome proliferator-induced transcriptional repression of nonperoxisomal gene expression in mouse.
Biochem. Biophys. Res. Commun. 230: 155-8, 1997.
309)  Rosenbaum K, Schaffrath B, Hagen WR, Jahnke K, Gonzalez FJ, Cook PF, Schnackerz KD.
Purification, characterization, and kinetics of porcine recombinant dihydropyrimidine dehydrogenase.
Protein Expr. Purif. 10: 185-91, 1997.
310)  Gonzalez FJ.
Recent update on the PPAR alpha-null mouse.
Biochimie. 79: 139-44, 1997.
311)  Mihara K, Otani K, Suzuki A, Yasui N, Nakano H, Meng X, Ohkubo T, Nagasaki T, Kaneko S, Tsuchida S, Sugawara K, Gonzalez FJ.
Relationship between the CYP2D6 genotype and the steady-state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine.
Psychopharmacology (Berl.). 133: 95-8, 1997.
312)  Shou M, Korzekwa KR, Brooks EN, Krausz KW, Gonzalez FJ, Gelboin HV.
Role of human hepatic cytochrome P450 1A2 and 3A4 in the metabolic activation of estrone.
Carcinogenesis. 18: 207-14, 1997.
313)  Peters JM, Cattley RC, Gonzalez FJ.
Role of PPAR alpha in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14,643.
Carcinogenesis. 18: 2029-33, 1997.
314)  Lee YH, Williams SC, Baer M, Sterneck E, Gonzalez FJ, Johnson PF.
The ability of C/EBP beta but not C/EBP alpha to synergize with an Sp1 protein is specified by the leucine zipper and activation domain.
Mol. Cell. Biol. 17: 2038-47, 1997.
315)  Gonzalez FJ.
The role of carcinogen-metabolizing enzyme polymorphisms in cancer susceptibility.
Reprod. Toxicol. 11: 397-412, 1997.
316)  Gonzalez FJ.
The role of peroxisome proliferator activated receptor alpha in peroxisome proliferation, physiological homeostasis, and chemical carcinogenesis.
Adv. Exp. Med. Biol. 422: 109-25, 1997.
317)  Nakajima T, Wang RS, Elovaara E, Gonzalez FJ, Gelboin HV, Raunio H, Pelkonen O, Vainio H, Aoyama T.
Toluene metabolism by cDNA-expressed human hepatic cytochrome P450.
Biochem. Pharmacol. 53: 271-7, 1997.
318)  Yokoi T, Kosaka Y, Chida M, Chiba K, Nakamura H, Ishizaki T, Kinoshita M, Sato K, Gonzalez FJ, Kamataki T.
A new CYP2D6 allele with a nine base insertion in exon 9 in a Japanese population associated with poor metabolizer phenotype.
Pharmacogenetics. 6: 395-401, 1996.
319)  Pineau T, Hudgins WR, Liu L, Chen LC, Sher T, Gonzalez FJ, Samid D.
Activation of a human peroxisome proliferator-activated receptor by the antitumor agent phenylacetate and its analogs.
Biochem. Pharmacol. 52: 659-67, 1996.
320)  Fernandez-Salguero PM, Hilbert DM, Rudikoff S, Ward JM, Gonzalez FJ.
Aryl-hydrocarbon receptor-deficient mice are resistant to 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced toxicity.
Toxicol. Appl. Pharmacol. 140: 173-9, 1996.
321)  Liu C, Zhuo X, Gonzalez FJ, Ding X.
Baculovirus-mediated expression and characterization of rat CYP2A3 and human CYP2A6: role in metabolic activation of nasal toxicants.
Mol. Pharmacol. 50: 781-8, 1996.
322)  Gonzalez FJ, Lee YH.
Constitutive expression of hepatic cytochrome P450 genes.
FASEB J. 10: 1112-7, 1996.
323)  FitzGerald CT, Fernandez-Salguero P, Gonzalez FJ, Nebert DW, Puga A.
Differential regulation of mouse Ah receptor gene expression in cell lines of different tissue origins.
Arch. Biochem. Biophys. 333: 170-8, 1996.
324)  Ono S, Hatanaka T, Miyazawa S, Tsutsui M, Aoyama T, Gonzalez FJ, Satoh T.
Human liver microsomal diazepam metabolism using cDNA-expressed cytochrome P450s: role of CYP2B6, 2C19 and the 3A subfamily.
Xenobiotica. 26: 1155-66, 1996.
325)  Gelboin HV, Goldfarb I, Krausz KW, Grogan J, Korzekwa KR, Gonzalez FJ, Shou M.
Inhibitory and noninhibitory monoclonal antibodies to human cytochrome P450 2E1.
Chem. Res. Toxicol. 9: 1023-30, 1996.
326)  Shou M, Krausz KW, Gonzalez FJ, Gelboin HV.
Metabolic activation of the potent carcinogen dibenzo[a,h]anthracene by cDNA-expressed human cytochromes P450.
Arch. Biochem. Biophys. 328: 201-7, 1996.
327)  Shou M, Krausz KW, Gonzalez FJ, Gelboin HV.
Metabolic activation of the potent carcinogen dibenzo[a,l]pyrene by human recombinant cytochromes P450, lung and liver microsomes.
Carcinogenesis. 17: 2429-33, 1996.
328)  Thornton-Manning J, Appleton ML, Gonzalez FJ, Yost GS.
Metabolism of 3-methylindole by vaccinia-expressed P450 enzymes: correlation of 3-methyleneindolenine formation and protein-binding.
J. Pharmacol. Exp. Ther. 276: 21-9, 1996.
329)  Wei X, McLeod HL, McMurrough J, Gonzalez FJ, Fernandez-Salguero P.
Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity.
J. Clin. Invest. 98: 610-5, 1996.
330)  Daly AK, Brockmöller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ, Huang JD, Idle JR, Ingelman-Sundberg M, Ishizaki T, Jacqz-Aigrain E, Meyer UA, Nebert DW, Steen VM, Wolf CR, Zanger UM.
Nomenclature for human CYP2D6 alleles.
Pharmacogenetics. 6: 193-201, 1996.
331)  Peters JM, Zhou YC, Ram PA, Lee SS, Gonzalez FJ, Waxman DJ.
Peroxisome proliferator-activated receptor alpha required for gene induction by dehydroepiandrosterone-3 beta-sulfate.
Mol. Pharmacol. 50: 67-74, 1996.
332)  Ryu DY, Levi PE, Fernandez-Salguero P, Gonzalez FJ, Hodgson E.
Piperonyl butoxide and acenaphthylene induce cytochrome P450 1A2 and 1B1 mRNA in aromatic hydrocarbon-responsive receptor knock-out mouse liver.
Mol. Pharmacol. 50: 443-6, 1996.
333)  Valentine JL, Lee SS, Seaton MJ, Asgharian B, Farris G, Corton JC, Gonzalez FJ, Medinsky MA.
Reduction of benzene metabolism and toxicity in mice that lack CYP2E1 expression.
Toxicol. Appl. Pharmacol. 141: 205-13, 1996.
334)  Zsnfernandez-Salguer P, Gonzalez FJ, Ward JM.
Response: hepatic fibrosis in ahr-/- mice.
Science. 271: 224, 1996.
335)  Buters JT, Tang BK, Pineau T, Gelboin HV, Kimura S, Gonzalez FJ.
Role of CYP1A2 in caffeine pharmacokinetics and metabolism: studies using mice deficient in CYP1A2.
Pharmacogenetics. 6: 291-6, 1996.
336)  Lee SS, Buters JT, Pineau T, Fernandez-Salguero P, Gonzalez FJ.
Role of CYP2E1 in the hepatotoxicity of acetaminophen.
Journal of biological chemistry. 271: 12063-7, 1996.
337)  Shou M, Korzekwa KR, Krausz KW, Buters JT, Grogan J, Goldfarb I, Hardwick JP, Gonzalez FJ, Gelboin HV.
Specificity of cDNA-expressed human and rodent cytochrome P450s in the oxidative metabolism of the potent carcinogen 7,12-dimethylbenz[a]anthracene.
Mol. Carcinog. 17: 241-9, 1996.
338)  Ono S, Hatanaka T, Hotta H, Satoh T, Gonzalez FJ, Tsutsui M.
Specificity of substrate and inhibitor probes for cytochrome P450s: evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes.
Xenobiotica. 26: 681-93, 1996.
339)  Nakagawa T, Sawada M, Gonzalez FJ, Yokoi T, Kamataki T.
Stable expression of human CYP2E1 in Chinese hamster cells: high sensitivity to N,N-dimethylnitrosamine in cytotoxicity testing.
Mutat. Res. 360: 181-6, 1996.
340)  Shou M, Gonzalez FJ, Gelboin HV.
Stereoselective epoxidation and hydration at the K-region of polycyclic aromatic hydrocarbons by cDNA-expressed cytochromes P450 1A1, 1A2, and epoxide hydrolase.
Biochemistry. 35: 15807-13, 1996.
341)  Tracy TS, Marra C, Wrighton SA, Gonzalez FJ, Korzekwa KR.
Studies of flurbiprofen 4'-hydroxylation. Additional evidence suggesting the sole involvement of cytochrome P450 2C9.
Biochem. Pharmacol. 52: 1305-9, 1996.
342)  Fernandez-Salguero PM, Gonzalez FJ.
Targeted disruption of specific cytochromes P450 and xenobiotic receptor genes.
Meth. Enzymol. 272: 412-30, 1996.
343)  Lee SS, Gonzalez FJ.
Targeted disruption of the peroxisome proliferator-activated receptor alpha gene, PPAR alpha.
Ann. N. Y. Acad. Sci. 804: 524-9, 1996.
344)  Devchand PR, Keller H, Peters JM, Vazquez M, Gonzalez FJ, Wahli W.
The PPARalpha-leukotriene B4 pathway to inflammation control.
Nature. 384: 39-43, 1996.
345)  Gonzalez FJ, Fernandez-Salguero P, Ward JM.
The role of the aryl hydrocarbon receptor in animal development, physiological homeostasis and toxicity of TCDD.
J Toxicol Sci. 21: 273-7, 1996.
346)  Kimura S, Hara Y, Pineau T, Fernandez-Salguero P, Fox CH, Ward JM, Gonzalez FJ.
The T/ebp null mouse: thyroid-specific enhancer-binding protein is essential for the organogenesis of the thyroid, lung, ventral forebrain, and pituitary.
Genes Dev. 10: 60-9, 1996.
347)  Lee IJ, Jeong KS, Roberts BJ, Kallarakal AT, Fernandez-Salguero P, Gonzalez FJ, Song BJ.
Transcriptional induction of the cytochrome P4501A1 gene by a thiazolium compound, YH439.
Mol. Pharmacol. 49: 980-8, 1996.
348)  Gonzalez FJ.
Use of transgenic animals in carcinogenesis studies.
Mol. Carcinog. 16: 63-7, 1996.
349)  Grogan J, Shou M, Andrusiak EA, Tamura S, Buters JT, Gonzalez FJ, Korzekwa KR.
Cytochrome P450 2A1, 2E1, and 2C9 cDNA-expression by insect cells and partial purification using hydrophobic chromatography.
Biochem. Pharmacol. 50: 1509-15, 1995.
350)  Furuya H, Fernandez-Salguero P, Gregory W, Taber H, Steward A, Gonzalez FJ, Idle JR.
Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy.
Pharmacogenetics. 5: 389-92, 1995.
351)  Gelboin HV, Krausz KW, Goldfarb I, Buters JT, Yang SK, Gonzalez FJ, Korzekwa KR, Shou M.
Inhibitory and non-inhibitory monoclonal antibodies to human cytochrome P450 3A3/4.
Biochem. Pharmacol. 50: 1841-50, 1995.
352)  Aranega AE, Velez MC, Gonzalez FJ, Melguizo C, Prados JC, Aranega A.
Modulation of cardiac intermediate filament proteins in the chick heart by fibric acid derivatives.
Eur J Morphol. 33: 421-31, 1995.
353)  Hoffman SM, Fernandez-Salguero P, Gonzalez FJ, Mohrenweiser HW.
Organization and evolution of the cytochrome P450 CYP2A-2B-2F subfamily gene cluster on human chromosome 19.
J. Mol. Evol. 41: 894-900, 1995.
354)  Gonzalez FJ, Fernandez-Salguero P, Lee SS, Pineau T, Ward JM.
Xenobiotic receptor knockout mice.
Toxicol. Lett. 82-83: 117-21, 1995.
355)  Ma X, Chen C, Krausz KW, Idle JR, Gonzalez FJ.
A metabolomic perspective of melatonin metabolism in the mouse.
Endocrinology. 149: 1869-79, 2008.
356)  Uno S, Dragin N, Miller ML, Dalton TP, Gonzalez FJ, Nebert DW.
Basal and inducible CYP1 mRNA quantitation and protein localization throughout the mouse gastrointestinal tract.
Free Radic. Biol. Med. 44: 570-83, 2008.
357)  Holdener M, Hintermann E, Bayer M, Rhode A, Rodrigo E, Hintereder G, Johnson EF, Gonzalez FJ, Pfeilschifter J, Manns MP, Herrath MG, Christen U.
Breaking tolerance to the natural human liver autoantigen cytochrome P450 2D6 by virus infection.
J. Exp. Med. 205: 1409-22, 2008.
358)  Nakajima T, Tanaka N, Sugiyama E, Kamijo Y, Hara A, Hu R, Li G, Li Y, Nakamura K, Gonzalez FJ, Aoyama T.
Cholesterol-lowering effect of bezafibrate is independent of peroxisome proliferator-activated receptor activation in mice.
Biochem. Pharmacol. 76: 108-19, 2008.
359)  Felmlee MA, Lon HK, Gonzalez FJ, Yu AM.
Cytochrome P450 expression and regulation in CYP3A4/CYP2D6 double transgenic humanized mice.
Drug Metab. Dispos. 36: 435-41, 2008.
360)  Dostalek M, Hardy KD, Milne GL, Morrow JD, Chen C, Gonzalez FJ, Gu J, Ding X, Johnson DA, Johnson JA, Martin MV, Guengerich FP.
Development of oxidative stress by cytochrome P450 induction in rodents is selective for barbiturates and related to loss of pyridine nucleotide-dependent protective systems.
J. Biol. Chem. 283: 17147-57, 2008.
361)  Takashima K, Ito Y, Gonzalez FJ, Nakajima T.
Different mechanisms of DEHP-induced hepatocellular adenoma tumorigenesis in wild-type and Ppar alpha-null mice.
J Occup Health. 50: 169-80, 2008.
362)  Hossain MA, Tsujita M, Gonzalez FJ, Yokoyama S.
Effects of fibrate drugs on expression of ABCA1 and HDL biogenesis in hepatocytes.
J. Cardiovasc. Pharmacol. 51: 258-66, 2008.
363)  Matsusue K, Kusakabe T, Noguchi T, Takiguchi S, Suzuki T, Yamano S, Gonzalez FJ.
Hepatic steatosis in leptin-deficient mice is promoted by the PPARgamma target gene Fsp27.
Cell Metab. 7: 302-11, 2008.
364)  Ohguchi H, Tanaka T, Uchida A, Magoori K, Kudo H, Kim I, Daigo K, Sakakibara I, Okamura M, Harigae H, Sasaki T, Osborne TF, Gonzalez FJ, Hamakubo T, Kodama T, Sakai J.
Hepatocyte nuclear factor 4alpha contributes to thyroid hormone homeostasis by cooperatively regulating the type 1 iodothyronine deiodinase gene with GATA4 and Kruppel-like transcription factor 9.
Mol. Cell. Biol. 28: 3917-31, 2008.
365)  Ahn SH, Shah YM, Inoue J, Morimura K, Kim I, Yim S, Lambert G, Kurotani R, Nagashima K, Gonzalez FJ, Inoue Y.
Hepatocyte nuclear factor 4alpha in the intestinal epithelial cells protects against inflammatory bowel disease.
Inflamm. Bowel Dis. 14: 908-20, 2008.
366)  Shah YM, Ito S, Morimura K, Chen C, Yim SH, Haase VH, Gonzalez FJ.
Hypoxia-inducible factor augments experimental colitis through an MIF-dependent inflammatory signaling cascade.
Gastroenterology. 134: 2036-48, 2048.e1-3, 2008.
367)  Chen C, Krausz KW, Idle JR, Gonzalez FJ.
Identification of novel toxicity-associated metabolites by metabolomics and mass isotopomer analysis of acetaminophen metabolism in wild-type and Cyp2e1-null mice.
J. Biol. Chem. 283: 4543-59, 2008.
368)  Hollingshead HE, Borland MG, Billin AN, Willson TM, Gonzalez FJ, Peters JM.
Ligand activation of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) and inhibition of cyclooxygenase 2 (COX2) attenuate colon carcinogenesis through independent signaling mechanisms.
Carcinogenesis. 29: 169-76, 2008.
369)  Sato S, Shirakawa H, Tomita S, Ohsaki Y, Haketa K, Tooi O, Santo N, Tohkin M, Furukawa Y, Gonzalez FJ, Komai M.
Low-dose dioxins alter gene expression related to cholesterol biosynthesis, lipogenesis, and glucose metabolism through the aryl hydrocarbon receptor-mediated pathway in mouse liver.
Toxicol. Appl. Pharmacol. 229: 10-9, 2008.
370)  Chen C, Shah YM, Morimura K, Krausz KW, Miyazaki M, Richardson TA, Morgan ET, Ntambi JM, Idle JR, Gonzalez FJ.
Metabolomics reveals that hepatic stearoyl-CoA desaturase 1 downregulation exacerbates inflammation and acute colitis.
Cell metabolism. 7: 135-47, 2008.
371)  Zhang H, Bosch-Marce M, Shimoda LA, Tan YS, Baek JH, Wesley JB, Gonzalez FJ, Semenza GL.
Mitochondrial autophagy is an HIF-1-dependent adaptive metabolic response to hypoxia.
J. Biol. Chem. 283: 10892-903, 2008.
372)  Smith NF, Baker SD, Gonzalez FJ, Harris JW, Figg WD, Sparreboom A.
Modulation of erlotinib pharmacokinetics in mice by a novel cytochrome P450 3A4 inhibitor, BAS 100.
Br. J. Cancer. 98: 1630-2, 2008.
373)  Shan W, Nicol CJ, Ito S, Bility MT, Kennett MJ, Ward JM, Gonzalez FJ, Peters JM.
Peroxisome proliferator-activated receptor-beta/delta protects against chemically induced liver toxicity in mice.
Hepatology. 47: 225-35, 2008.
374)  Dragin N, Shi Z, Madan R, Karp CL, Sartor MA, Chen C, Gonzalez FJ, Nebert DW.
Phenotype of the Cyp1a1/1a2/1b1-/- triple-knockout mouse.
Mol. Pharmacol. 73: 1844-56, 2008.
375)  Tanaka N, Moriya K, Kiyosawa K, Koike K, Gonzalez FJ, Aoyama T.
PPARalpha activation is essential for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma in mice.
J. Clin. Invest. 118: 683-94, 2008.
376)  Gonzalez FJ, Shah YM.
PPARalpha: mechanism of species differences and hepatocarcinogenesis of peroxisome proliferators.
Toxicology. 246: 2-8, 2008.
377)  Tyburski JB, Patterson AD, Krausz KW, Slavik J, Fornace AJ, Gonzalez FJ, Idle JR.
Radiation metabolomics. 1. Identification of minimally invasive urine biomarkers for gamma-radiation exposure in mice.
Radiat. Res. 170: 1-14, 2008.
378)  Vasiliou V, Gonzalez FJ.
Role of CYP1B1 in glaucoma.
Annu. Rev. Pharmacol. Toxicol. 48: 333-58, 2008.
379)  Kang JS, Wanibuchi H, Morimura K, Wongpoomchai R, Chusiri Y, Gonzalez FJ, Fukushima S.
Role of CYP2E1 in thioacetamide-induced mouse hepatotoxicity.
Toxicol. Appl. Pharmacol. 228: 295-300, 2008.
380)  Peters JM, Hollingshead HE, Gonzalez FJ.
Role of peroxisome-proliferator-activated receptor beta/delta (PPARbeta/delta) in gastrointestinal tract function and disease.
Clin. Sci. 115: 107-27, 2008.
381)  Wang T, Ma X, Krausz KW, Idle JR, Gonzalez FJ.
Role of pregnane X receptor in control of all-trans retinoic acid (ATRA) metabolism and its potential contribution to ATRA resistance.
J. Pharmacol. Exp. Ther. 324: 674-84, 2008.
382)  Yanagiba Y, Ito Y, Yamanoshita O, Zhang SY, Watanabe G, Taya K, Li CM, Inotsume Y, Kamijima M, Gonzalez FJ, Nakajima T.
Styrene trimer may increase thyroid hormone levels via down-regulation of the aryl hydrocarbon receptor (AhR) target gene UDP-glucuronosyltransferase.
Environ. Health Perspect. 116: 740-5, 2008.
383)  Ma X, Idle JR, Gonzalez FJ.
The pregnane X receptor: from bench to bedside.
Expert opinion on drug metabolism & toxicology. 4: 895-908, 2008.
384)  Saji T, Kikuchi R, Kusuhara H, Kim I, Gonzalez FJ, Sugiyama Y.
Transcriptional regulation of human and mouse organic anion transporter 1 by hepatocyte nuclear factor 1 alpha/beta.
J. Pharmacol. Exp. Ther. 324: 784-90, 2008.
385)  Villalobos-Molina R, Vazquez-Cuevas FG, Lopez-Guerrero JJ, Figueroa-Garcia MC, Gallardo-Ortiz IA, Ibarra M, Rodriguez-Sosa M, Gonzalez FJ, Elizondo G.
Vascular alpha-adrenoceptors are overexpressed in aorta of the aryl hydrocarbon receptor null mouse: role of increased angiotensin II.
Auton Autacoid Pharmacol. 28: 61-7, 2008.
386)  Chen C, Ma X, Malfatti MA, Krausz KW, Kimura S, Felton JS, Idle JR, Gonzalez FJ.
A comprehensive investigation of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) metabolism in the mouse using a multivariate data analysis approach.
Chemical research in toxicology. 20: 531-42, 2007.
387)  Ichihara S, Yamada Y, Ichihara G, Nakajima T, Li P, Kondo T, Gonzalez FJ, Murohara T.
A role for the aryl hydrocarbon receptor in regulation of ischemia-induced angiogenesis.
Arterioscler. Thromb. Vasc. Biol. 27: 1297-304, 2007.
388)  Gonzalez FJ.
Animal models for human risk assessment: the peroxisome proliferator-activated receptor alpha-humanized mouse.
Nutr. Rev. 65: S2-6, 2007.
389)  Arpiainen S, Lämsä V, Pelkonen O, Yim SH, Gonzalez FJ, Hakkola J.
Aryl hydrocarbon receptor nuclear translocator and upstream stimulatory factor regulate Cytochrome P450 2a5 transcription through a common E-box site.
J. Mol. Biol. 369: 640-52, 2007.
390)  Xu Y, Zhou YL, Gonzalez FJ, Snead ML.
CCAAT/enhancer-binding protein delta (C/EBPdelta) maintains amelogenin expression in the absence of C/EBPalpha in vivo.
J. Biol. Chem. 282: 29882-9, 2007.
391)  Sumi K, Tanaka T, Uchida A, Magoori K, Urashima Y, Ohashi R, Ohguchi H, Okamura M, Kudo H, Daigo K, Maejima T, Kojima N, Sakakibara I, Jiang S, Hasegawa G, Kim I, Osborne TF, Naito M, Gonzalez FJ, Hamakubo T, Kodama T, Sakai J.
Cooperative interaction between hepatocyte nuclear factor 4 alpha and GATA transcription factors regulates ATP-binding cassette sterol transporters ABCG5 and ABCG8.
Mol. Cell. Biol. 27: 4248-60, 2007.
392)  Matsumoto K, Yu S, Jia Y, Ahmed MR, Viswakarma N, Sarkar J, Kashireddy PV, Rao MS, Karpus W, Gonzalez FJ, Reddy JK.
Critical role for transcription coactivator peroxisome proliferator-activated receptor (PPAR)-binding protein/TRAP220 in liver regeneration and PPARalpha ligand-induced liver tumor development.
Journal of biological chemistry. 282: 17053-60, 2007.
393)  Gonzalez FJ.
CYP3A4 and pregnane X receptor humanized mice.
J. Biochem. Mol. Toxicol. 21: 158-62, 2007.
394)  Ito Y, Yamanoshita O, Asaeda N, Tagawa Y, Lee CH, Aoyama T, Ichihara G, Furuhashi K, Kamijima M, Gonzalez FJ, Nakajima T.
Di(2-ethylhexyl)phthalate induces hepatic tumorigenesis through a peroxisome proliferator-activated receptor alpha-independent pathway.
Journal of occupational health. 49: 172-82, 2007.
395)  Ito S, Chen C, Satoh J, Yim S, Gonzalez FJ.
Dietary phytochemicals regulate whole-body CYP1A1 expression through an arylhydrocarbon receptor nuclear translocator-dependent system in gut.
J. Clin. Invest. 117: 1940-50, 2007.
396)  Kim I, Ahn SH, Inagaki T, Choi M, Ito S, Guo GL, Kliewer SA, Gonzalez FJ.
Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine.
J. Lipid Res. 48: 2664-72, 2007.
397)  Shah YM, Morimura K, Gonzalez FJ.
Expression of peroxisome proliferator-activated receptor-gamma in macrophage suppresses experimentally induced colitis.
Am. J. Physiol. Gastrointest. Liver Physiol. 292: G657-66, 2007.
398)  Reddy AB, Maywood ES, Karp NA, King VM, Inoue Y, Gonzalez FJ, Lilley KS, Kyriacou CP, Hastings MH.
Glucocorticoid signaling synchronizes the liver circadian transcriptome.
Hepatology. 45: 1478-88, 2007.
399)  Mandard S, Stienstra R, Escher P, Tan NS, Kim I, Gonzalez FJ, Wahli W, Desvergne B, Müller M, Kersten S.
Glycogen synthase 2 is a novel target gene of peroxisome proliferator-activated receptors.
Cell. Mol. Life Sci. 64: 1145-57, 2007.
400)  Yang Q, Ito S, Gonzalez FJ.
Hepatocyte-restricted constitutive activation of PPAR alpha induces hepatoproliferation but not hepatocarcinogenesis.
Carcinogenesis. 28: 1171-7, 2007.
401)  Duan SZ, Ivashchenko CY, Whitesall SE, D'Alecy LG, Duquaine DC, Brosius FC, Gonzalez FJ, Vinson C, Pierre MA, Milstone DS, Mortensen RM.
Hypotension, lipodystrophy, and insulin resistance in generalized PPARgamma-deficient mice rescued from embryonic lethality.
J. Clin. Invest. 117: 812-22, 2007.
402)  Chen C, Gonzalez FJ, Idle JR.
LC-MS-based metabolomics in drug metabolism.
Drug Metab. Rev. 39: 581-97, 2007.
403)  Burdick AD, Bility MT, Girroir EE, Billin AN, Willson TM, Gonzalez FJ, Peters JM.
Ligand activation of peroxisome proliferator-activated receptor-beta/delta(PPARbeta/delta) inhibits cell growth of human N/TERT-1 keratinocytes.
Cell. Signal. 19: 1163-71, 2007.
404)  Hevener AL, Olefsky JM, Reichart D, Nguyen MT, Bandyopadyhay G, Leung HY, Watt MJ, Benner C, Febbraio MA, Nguyen AK, Folian B, Subramaniam S, Gonzalez FJ, Glass CK, Ricote M.
Macrophage PPAR gamma is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones.
J. Clin. Invest. 117: 1658-69, 2007.
405)  Idle JR, Gonzalez FJ.
Cell Metab. 6: 348-51, 2007.
406)  Ma X, Idle JR, Malfatti MA, Krausz KW, Nebert DW, Chen CS, Felton JS, Waxman DJ, Gonzalez FJ.
Mouse lung CYP1A1 catalyzes the metabolic activation of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP).
Carcinogenesis. 28: 732-7, 2007.
407)  Kamijo Y, Hora K, Nakajima T, Kono K, Takahashi K, Ito Y, Higuchi M, Kiyosawa K, Shigematsu H, Gonzalez FJ, Aoyama T.
Peroxisome proliferator-activated receptor alpha protects against glomerulonephritis induced by long-term exposure to the plasticizer di-(2-ethylhexyl)phthalate.
J. Am. Soc. Nephrol. 18: 176-88, 2007.
408)  Shah YM, Morimura K, Yang Q, Tanabe T, Takagi M, Gonzalez FJ.
Peroxisome proliferator-activated receptor alpha regulates a microRNA-mediated signaling cascade responsible for hepatocellular proliferation.
Mol. Cell. Biol. 27: 4238-47, 2007.
409)  Hollingshead HE, Killins RL, Borland MG, Girroir EE, Billin AN, Willson TM, Sharma AK, Amin S, Gonzalez FJ, Peters JM.
Peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) ligands do not potentiate growth of human cancer cell lines.
Carcinogenesis. 28: 2641-9, 2007.
410)  Thorp E, Kuriakose G, Shah YM, Gonzalez FJ, Tabas I.
Pioglitazone increases macrophage apoptosis and plaque necrosis in advanced atherosclerotic lesions of nondiabetic low-density lipoprotein receptor-null mice.
Circulation. 116: 2182-90, 2007.
411)  Kamijo Y, Hora K, Kono K, Takahashi K, Higuchi M, Ehara T, Kiyosawa K, Shigematsu H, Gonzalez FJ, Aoyama T.
PPARalpha protects proximal tubular cells from acute fatty acid toxicity.
J. Am. Soc. Nephrol. 18: 3089-100, 2007.
412)  Shah YM, Ma X, Morimura K, Kim I, Gonzalez FJ.
Pregnane X receptor activation ameliorates DSS-induced inflammatory bowel disease via inhibition of NF-kappaB target gene expression.
Am. J. Physiol. Gastrointest. Liver Physiol. 292: G1114-22, 2007.
413)  Medina-Díaz IM, Arteaga-Illán G, de León MB, Cisneros B, Sierra-Santoyo A, Vega L, Gonzalez FJ, Elizondo G.
Pregnane X receptor-dependent induction of the CYP3A4 gene by o,p'-1,1,1,-trichloro-2,2-bis (p-chlorophenyl)ethane.
Drug Metab. Dispos. 35: 95-102, 2007.
414)  Kikuchi R, Kusuhara H, Hattori N, Kim I, Shiota K, Gonzalez FJ, Sugiyama Y.
Regulation of tissue-specific expression of the human and mouse urate transporter 1 gene by hepatocyte nuclear factor 1 alpha/beta and DNA methylation.
Mol. Pharmacol. 72: 1619-25, 2007.
415)  Ma X, Shah YM, Guo GL, Wang T, Krausz KW, Idle JR, Gonzalez FJ.
Rifaximin is a gut-specific human pregnane X receptor activator.
J. Pharmacol. Exp. Ther. 322: 391-8, 2007.
416)  Kang JS, Wanibuchi H, Morimura K, Gonzalez FJ, Fukushima S.
Role of CYP2E1 in diethylnitrosamine-induced hepatocarcinogenesis in vivo.
Cancer Res. 67: 11141-6, 2007.
417)  Wolf KK, Wood SG, Allard JL, Hunt JA, Gorman N, Walton-Strong BW, Szakacs JG, Duan SX, Hao Q, Court MH, von Moltke LL, Greenblatt DJ, Kostrubsky V, Jeffery EH, Wrighton SA, Gonzalez FJ, Sinclair PR, Sinclair JF.
Role of CYP3A and CYP2E1 in alcohol-mediated increases in acetaminophen hepatotoxicity: comparison of wild-type and Cyp2e1(-/-) mice.
Drug Metab. Dispos. 35: 1223-31, 2007.
418)  Kim I, Morimura K, Shah Y, Yang Q, Ward JM, Gonzalez FJ.
Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice.
Carcinogenesis. 28: 940-6, 2007.
419)  Gonzalez FJ.
The 2006 Bernard B. Brodie Award Lecture. Cyp2e1.
Drug Metab. Dispos. 35: 1-8, 2007.
420)  Dongol B, Shah Y, Kim I, Gonzalez FJ, Hunt MC.
The acyl-CoA thioesterase I is regulated by PPAR{alpha} and HNF4{alpha} via a distal response element in the promoter.
J. Lipid Res. 48: 1781-91, 2007.
421)  Giri S, Krausz KW, Idle JR, Gonzalez FJ.
The metabolomics of (+/-)-arecoline 1-oxide in the mouse and its formation by human flavin-containing monooxygenases.
Biochem. Pharmacol. 73: 561-73, 2007.
422)  Ma X, Shah Y, Cheung C, Guo GL, Feigenbaum L, Krausz KW, Idle JR, Gonzalez FJ.
The pregnane X receptor gene-humanized mouse: a model for investigating drug-drug interactions mediated by cytochromes P450 3A.
Drug Metab. Dispos. 35: 194-200, 2007.
423)  Zhen Y, Slanar O, Krausz KW, Chen C, Slavík J, McPhail KL, Zabriskie TM, Perlík F, Gonzalez FJ, Idle JR.
3,4-Dehydrodebrisoquine, a novel debrisoquine metabolite formed from 4-hydroxydebrisoquine that affects the CYP2D6 metabolic ratio.
Drug Metab. Dispos. 34: 1563-74, 2006.
424)  Ueda R, Iketaki H, Nagata K, Kimura S, Gonzalez FJ, Kusano K, Yoshimura T, Yamazoe Y.
A common regulatory region functions bidirectionally in transcriptional activation of the human CYP1A1 and CYP1A2 genes.
Mol. Pharmacol. 69: 1924-30, 2006.
425)  Giri S, Idle JR, Chen C, Zabriskie TM, Krausz KW, Gonzalez FJ.
A metabolomic approach to the metabolism of the areca nut alkaloids arecoline and arecaidine in the mouse.
Chem. Res. Toxicol. 19: 818-27, 2006.
426)  Meng LH, Shankavaram U, Chen C, Agama K, Fu HQ, Gonzalez FJ, Weinstein J, Pommier Y.
Activation of Aminoflavone (NSC 686288) by a Sulfotransferase Is Required for the Antiproliferative Effect of the Drug and for Induction of Histone {gamma}-H2AX.
Cancer Res. 66: 9656-64, 2006.
427)  Zhang Y, Lee FY, Barrera G, Lee H, Vales C, Gonzalez FJ, Willson TM, Edwards PA.
Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice.
Proc. Natl. Acad. Sci. U.S.A. 103: 1006-11, 2006.
428)  Yang Q, Yamada A, Kimura S, Peters JM, Gonzalez FJ.
Alterations in skin and stratified epithelia by constitutively activated PPARalpha.
J. Invest. Dermatol. 126: 374-85, 2006.
429)  Maher JM, Slitt AL, Callaghan TN, Cheng X, Cheung C, Gonzalez FJ, Klaassen CD.
Alterations in transporter expression in liver, kidney, and duodenum after targeted disruption of the transcription factor HNF1alpha.
Biochem. Pharmacol. 72: 512-22, 2006.
430)  Hanniman EA, Lambert G, Inoue Y, Gonzalez FJ, Sinal CJ.
Apolipoprotein A-IV is regulated by nutritional and metabolic stress: involvement of glucocorticoids, HNF-4 alpha, and PGC-1 alpha.
J. Lipid Res. 47: 2503-14, 2006.
431)  Naito H, Yamanoshita O, Kamijima M, Katoh T, Matsunaga T, Lee CH, Kim H, Aoyama T, Gonzalez FJ, Nakajima T.
Association of V227A PPARalpha polymorphism with altered serum biochemistry and alcohol drinking in Japanese men.
Pharmacogenet. Genomics. 16: 569-77, 2006.
432)  Miyata M, Matsuda Y, Tsuchiya H, Kitada H, Akase T, Shimada M, Nagata K, Gonzalez FJ, Yamazoe Y.
Chenodeoxycholic acid-mediated activation of the farnesoid X receptor negatively regulates hydroxysteroid sulfotransferase.
Drug Metab. Pharmacokinet. 21: 315-23, 2006.
433)  Vasiliou V, Ziegler TL, Bludeau P, Petersen DR, Gonzalez FJ, Deitrich RA.
CYP2E1 and catalase influence ethanol sensitivity in the central nervous system.
Pharmacogenet. Genomics. 16: 51-8, 2006.
434)  Gonzalez FJ, Yu AM.
Cytochrome P450 and xenobiotic receptor humanized mice.
Annu. Rev. Pharmacol. Toxicol. 46: 41-64, 2006.
435)  Pedraza N, Rosell M, Villarroya J, Iglesias R, Gonzalez FJ, Solanes G, Villarroya F.
Developmental and Tissue-Specific Involvement of Peroxisome Proliferator-Activated Receptor-{alpha} in the Control of Mouse Uncoupling Protein-3 Gene Expression.
Endocrinology. 147: 4695-704, 2006.
436)  Morimura K, Cheung C, Ward JM, Reddy JK, Gonzalez FJ.
Differential susceptibility of mice humanized for peroxisome proliferator-activated receptor {alpha} to Wy-14,643-induced liver tumorigenesis.
. 27: 1074-1080, 2006.
437)  Yim SH, Shah Y, Tomita S, Morris HD, Gavrilova O, Lambert G, Ward JM, Gonzalez FJ.
Disruption of the Arnt gene in endothelial cells causes hepatic vascular defects and partial embryonic lethality in mice.
Hepatology. 44: 550-60, 2006.
438)  Guo GL, Santamarina-Fojo S, Akiyama TE, Amar MJ, Paigen BJ, Brewer B, Gonzalez FJ.
Effects of FXR in foam-cell formation and atherosclerosis development.
Biochim. Biophys. Acta. 1761: 1401-9, 2006.
439)  Zimatkin SM, Pronko SP, Vasiliou V, Gonzalez FJ, Deitrich RA.
Enzymatic mechanisms of ethanol oxidation in the brain.
Alcohol. Clin. Exp. Res. 30: 1500-5, 2006.
440)  Yamamoto Y, Moore R, Hess HA, Guo GL, Gonzalez FJ, Korach KS, Maronpot RR, Negishi M.
Estrogen receptor alpha mediates 17alpha-ethynylestradiol causing hepatotoxicity.
J. Biol. Chem. 281: 16625-31, 2006.
441)  Lee H, Zhang Y, Lee FY, Nelson SF, Gonzalez FJ, Edwards PA.
FXR regulates organic solute transporters alpha and beta in the adrenal gland, kidney, and intestine.
J. Lipid Res. 47: 201-14, 2006.
442)  Lee H, Gonzalez FJ, Yoon M.
Ginsenoside Rf, a component of ginseng, regulates lipoprotein metabolism through peroxisome proliferator-activated receptor alpha.
Biochem. Biophys. Res. Commun. 339: 196-203, 2006.
443)  Cheung C, Yu AM, Chen CS, Krausz KW, Byrd LG, Feigenbaum L, Edwards RJ, Waxman DJ, Gonzalez FJ.
Growth hormone determines sexual dimorphism of hepatic cytochrome P450 3A4 expression in transgenic mice.
J. Pharmacol. Exp. Ther. 316: 1328-34, 2006.
444)  Sugiyama E, Tanaka N, Nakajima T, Kamijo Y, Yokoyama S, Li Y, Gonzalez FJ, Aoyama T.
Haploinsufficiency in the PPARalpha and LDL receptor genes leads to gender- and age-specific obesity and hyperinsulinemia.
Biochem. Biophys. Res. Commun. 350: 370-6, 2006.
445)  Bosse T, van Wering HM, Gielen M, Dowling LN, Fialkovich JJ, Piaseckyj CM, Gonzalez FJ, Akiyama TE, Montgomery RK, Grand RJ, Krasinski SD.
Hepatocyte nuclear factor-1alpha is required for expression but dispensable for histone acetylation of the lactase-phlorizin hydrolase gene in vivo.
Am. J. Physiol. Gastrointest. Liver Physiol. 290: G1016-24, 2006.
446)  Miura A, Yamagata K, Kakei M, Hatakeyama H, Takahashi N, Fukui K, Nammo T, Yoneda K, Inoue Y, Sladek FM, Magnuson MA, Kasai H, Miyagawa J, Gonzalez FJ, Shimomura I.
Hepatocyte nuclear factor-4alpha is essential for glucose-stimulated insulin secretion by pancreatic beta-cells.
J. Biol. Chem. 281: 5246-57, 2006.
447)  Kamiya A, Gonzalez FJ, Nakauchi H.
Identification and differentiation of hepatic stem cells during liver development.
Front. Biosci. 11: 1302-10, 2006.
448)  Crosby MB, Zhang J, Nowling TM, Svenson JL, Nicol CJ, Gonzalez FJ, Gilkeson GS.
Inflammatory modulation of PPAR gamma expression and activity.
Clin. Immunol. 118: 276-83, 2006.
449)  Michalik L, Auwerx J, Berger JP, Chatterjee VK, Glass CK, Gonzalez FJ, Grimaldi PA, Kadowaki T, Lazar MA, O'Rahilly S, Palmer CN, Plutzky J, Reddy JK, Spiegelman BM, Staels B, Wahli W.
International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors.
Pharmacol. Rev. 58: 726-41, 2006.
450)  Marin HE, Peraza MA, Billin AN, Willson TM, Ward JM, Kennett MJ, Gonzalez FJ, Peters JM.
Ligand activation of peroxisome proliferator-activated receptor beta inhibits colon carcinogenesis.
Cancer Res. 66: 4394-401, 2006.
451)  Matsusue K, Miyoshi A, Yamano S, Gonzalez FJ.
Ligand-activated PPARbeta efficiently represses the induction of LXR-dependent promoter activity through competition with RXR.
Mol. Cell. Endocrinol. 256: 23-33, 2006.
452)  Uno S, Dalton TP, Dragin N, Curran CP, Derkenne S, Miller ML, Shertzer HG, Gonzalez FJ, Nebert DW.
Oral benzo[a]pyrene in Cyp1 knockout mouse lines: CYP1A1 important in detoxication, CYP1B1 metabolism required for immune damage independent of total-body burden and clearance rate.
Mol. Pharmacol. 69: 1103-14, 2006.
453)  Adachi M, Kurotani R, Morimura K, Shah Y, Sanford M, Madison BB, Gumucio DL, Marin HE, Peters JM, Young HA, Gonzalez FJ.
Peroxisome proliferator activated receptor gamma in colonic epithelial cells protects against experimental inflammatory bowel disease.
Gut. 55: 1104-13, 2006.
454)  Yang Q, Kurotani R, Yamada A, Kimura S, Gonzalez FJ.
Peroxisome Proliferator-Activated Receptor {alpha} Activation during Pregnancy Severely Impairs Mammary Lobuloalveolar Development in Mice.
Endocrinology. 147: 4772-80, 2006.
455)  Zhang X, Tanaka N, Nakajima T, Kamijo Y, Gonzalez FJ, Aoyama T.
Peroxisome proliferator-activated receptor alpha-independent peroxisome proliferation.
Biochem. Biophys. Res. Commun. 346: 1307-11, 2006.
456)  Kyrmizi I, Hatzis P, Katrakili N, Tronche F, Gonzalez FJ, Talianidis I.
Plasticity and expanding complexity of the hepatic transcription factor network during liver development.
Genes Dev. 20: 2293-305, 2006.
457)  Lee CH, Olson P, Hevener A, Mehl I, Chong LW, Olefsky JM, Gonzalez FJ, Ham J, Kang H, Peters JM, Evans RM.
PPARdelta regulates glucose metabolism and insulin sensitivity.
Proc. Natl. Acad. Sci. U.S.A. 103: 3444-9, 2006.
458)  Inoue Y, Yu AM, Yim SH, Ma X, Krausz KW, Inoue J, Xiang CC, Brownstein MJ, Eggertsen G, Björkhem I, Gonzalez FJ.
Regulation of bile acid biosynthesis by hepatocyte nuclear factor 4alpha.
J. Lipid Res. 47: 215-27, 2006.
459)  Ding X, Lichti K, Kim I, Gonzalez FJ, Staudinger JL.
Regulation of constitutive androstane receptor and its target genes by fasting, cAMP, hepatocyte nuclear factor alpha, and the coactivator peroxisome proliferator-activated receptor gamma coactivator-1alpha.
J. Biol. Chem. 281: 26540-51, 2006.
460)  Kikuchi R, Kusuhara H, Hattori N, Shiota K, Kim I, Gonzalez FJ, Sugiyama Y.
Regulation of the expression of human organic anion transporter 3 by hepatocyte nuclear factor 1alpha/beta and DNA methylation.
Mol. Pharmacol. 70: 887-96, 2006.
461)  Miyata M, Watase H, Hori W, Shimada M, Nagata K, Gonzalez FJ, Yamazoe Y.
Role for enhanced faecal excretion of bile acid in hydroxysteroid sulfotransferase-mediated protection against lithocholic acid-induced liver toxicity.
Xenobiotica. 36: 631-44, 2006.
462)  Gonzalez FJ.
Role of beta-catenin in the adult liver.
Hepatology. 43: 650-3, 2006.
463)  Inoue Y, Peters LL, Yim SH, Inoue J, Gonzalez FJ.
Role of hepatocyte nuclear factor 4alpha in control of blood coagulation factor gene expression.
J. Mol. Med. 84: 334-44, 2006.
464)  Gonzalez FJ.
Role of HNF4alpha in the superinduction of the IL-1beta-activated iNOS gene by oxidative stress.
Biochem. J. 394: e3-5, 2006.
465)  Narimatsu S, Takatsu N, Yamano S, Inoue Y, Hanioka N, Kiryu K, Naito S, Gonzalez FJ, Yamamoto S.
The effect of dimethyl sulfoxide on the function of cytochrome P450 2D6 in HepG2 cells upon the co-expression with NADPH-cytochrome P450 reductase.
Chem. Biol. Interact. 159: 47-57, 2006.
466)  Cariou B, van Harmelen K, Duran-Sandoval D, van Dijk TH, Grefhorst A, Abdelkarim M, Caron S, Torpier G, Fruchart JC, Gonzalez FJ, Kuipers F, Staels B.
The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice.
J. Biol. Chem. 281: 11039-49, 2006.
467)  Peraza MA, Burdick AD, Marin HE, Gonzalez FJ, Peters JM.
The toxicology of ligands for peroxisome proliferator-activated receptors (PPAR).
Toxicol. Sci. 90: 269-95, 2006.
468)  Ueno M, Tomita S, Ueki M, Iwanaga Y, Huang CL, Onodera M, Maekawa N, Gonzalez FJ, Sakamoto H.
Two pathways of apoptosis are simultaneously induced in the embryonal brains of neural cell-specific HIF-1alpha-deficient mice.
Histochem. Cell Biol. 125: 535-44, 2006.
469)  Chen C, Meng L, Ma X, Krausz KW, Pommier Y, Idle JR, Gonzalez FJ.
Urinary metabolite profiling reveals CYP1A2-mediated metabolism of NSC686288 (aminoflavone).
J. Pharmacol. Exp. Ther. 318: 1330-42, 2006.
470)  Ma X, Idle JR, Krausz KW, Tan DX, Ceraulo L, Gonzalez FJ.
Urinary metabolites and antioxidant products of exogenous melatonin in the mouse.
J. Pineal Res. 40: 343-9, 2006.
471)  Zhang H, Zhang A, Kohan DE, Nelson RD, Gonzalez FJ, Yang T.
Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention.
Proc Natl Acad Sci U S A. 102: 9406-11, 2005.
472)  Bradford BU, Kono H, Isayama F, Kosyk O, Wheeler MD, Akiyama TE, Bleye L, Krausz KW, Gonzalez FJ, Koop DR, Rusyn I.
Cytochrome P450 CYP2E1, but not nicotinamide adenine dinucleotide phosphate oxidase, is required for ethanol-induced oxidative DNA damage in rodent liver.
Hepatology. 41: 336-44, 2005.
473)  Clemencet MC, Muzio G, Trombetta A, Peters JM, Gonzalez FJ, Canuto RA, Latruffe N.
Differences in cell proliferation in rodent and human hepatic derived cell lines exposed to ciprofibrate.
Cancer Lett. 222: 217-26, 2005.
474)  Cheung C, Ma X, Krausz KW, Kimura S, Feigenbaum L, Dalton TP, Nebert DW, Idle JR, Gonzalez FJ.
Differential metabolism of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in mice humanized for CYP1A1 and CYP1A2.
Chem. Res. Toxicol. 18: 1471-8, 2005.
475)  Gonzalez FJ.
Getting fat: two new players in molecular adipogenesis.
Cell Metab. 1: 85-6, 2005.
476)  Barbier O, Girard H, Inoue Y, Duez H, Villeneuve L, Kamiya A, Fruchart JC, Guillemette C, Gonzalez FJ, Staels B.
Hepatic expression of the UGT1A9 gene is governed by hepatocyte nuclear factor 4alpha.
Mol Pharmacol. 67: 241-9, 2005.
477)  Gunton JE, Kulkarni RN, Yim S, Okada T, Hawthorne WJ, Tseng YH, Roberson RS, Ricordi C, O'Connell PJ, Gonzalez FJ, Kahn CR.
Loss of ARNT/HIF1beta mediates altered gene expression and pancreatic-islet dysfunction in human type 2 diabetes.
Cell. 122: 337-49, 2005.
478)  Ma X, Idle JR, Krausz KW, Gonzalez FJ.
Metabolism of melatonin by human cytochromes p450.
Drug Metab Dispos. 33: 489-94, 2005.
479)  Rodríguez-Sosa M, Elizondo G, López-Durán RM, Rivera I, Gonzalez FJ, Vega L.
Over-production of IFN-gamma and IL-12 in AhR-null mice.
FEBS Lett. 579: 6403-10, 2005.
480)  Crosby MB, Svenson JL, Zhang J, Nicol CJ, Gonzalez FJ, Gilkeson GS.
Peroxisome proliferation-activated receptor (PPAR)gamma is not necessary for synthetic PPARgamma agonist inhibition of inducible nitric-oxide synthase and nitric oxide.
J Pharmacol Exp Ther. 312: 69-76, 2005.
481)  Kim DJ, Murray IA, Burns AM, Gonzalez FJ, Perdew GH, Peters JM.
Peroxisome proliferator-activated receptor-beta/delta inhibits epidermal cell proliferation by down-regulation of kinase activity.
J Biol Chem. 280: 9519-27, 2005.
482)  Yu AM, Fukamachi K, Krausz KW, Cheung C, Gonzalez FJ.
Potential role for human cytochrome P450 3A4 in estradiol homeostasis.
Endocrinology. 146: 2911-9, 2005.
483)  Nicol CJ, Adachi M, Akiyama TE, Gonzalez FJ.
PPARgamma in endothelial cells influences high fat diet-induced hypertension.
Am J Hypertens. 18: 549-56, 2005.
484)  Duez H, Lefebvre B, Poulain P, Torra IP, Percevault F, Luc G, Peters JM, Gonzalez FJ, Gineste R, Helleboid S, Dzavik V, Fruchart JC, Fiévet C, Lefebvre P, Staels B.
Regulation of human apoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor alpha modulation.
Arterioscler Thromb Vasc Biol. 25: 585-91, 2005.
485)  Gonzalez FJ.
Role of cytochromes P450 in chemical toxicity and oxidative stress: studies with CYP2E1.
Mutat Res. 569: 101-10, 2005.
486)  Miyata M, Tozawa A, Otsuka H, Nakamura T, Nagata K, Gonzalez FJ, Yamazoe Y.
Role of farnesoid X receptor in the enhancement of canalicular bile acid output and excretion of unconjugated bile acids: a mechanism for protection against cholic acid-induced liver toxicity.
J Pharmacol Exp Ther. 312: 759-66, 2005.
487)  Hays T, Rusyn I, Burns AM, Kennett MJ, Ward JM, Gonzalez FJ, Peters JM.
Role of peroxisome proliferator-activated receptor-alpha (PPARalpha) in bezafibrate-induced hepatocarcinogenesis and cholestasis.
Carcinogenesis. 26: 219-27, 2005.
488)  Tong Y, Hara A, Komatsu M, Tanaka N, Kamijo Y, Gonzalez FJ, Aoyama T.
Suppression of expression of muscle-associated proteins by PPARalpha in brown adipose tissue.
Biochem Biophys Res Commun. 2005.
489)  Cheung C, Yu AM, Ward JM, Krausz KW, Akiyama TE, Feigenbaum L, Gonzalez FJ.
The cyp2e1-humanized transgenic mouse: role of cyp2e1 in acetaminophen hepatotoxicity.
Drug Metab Dispos. 33: 449-57, 2005.
490)  Duran-Sandoval D, Cariou B, Percevault F, Hennuyer N, Grefhorst A, van Dijk TH, Gonzalez FJ, Fruchart JC, Kuipers F, Staels B.
The farnesoid X receptor modulates hepatic carbohydrate metabolism during the fasting-refeeding transition.
J Biol Chem. 280: 29971-9, 2005.
491)  Fukui K, Yang Q, Cao Y, Takahashi N, Hatakeyama H, Wang H, Wada J, Zhang Y, Marselli L, Nammo T, Yoneda K, Onishi M, Higashiyama S, Matsuzawa Y, Gonzalez FJ, Weir GC, Kasai H, Shimomura I, Miyagawa J, Wollheim CB, Yamagata K.
The HNF-1 target collectrin controls insulin exocytosis by SNARE complex formation.
Cell metabolism. 2: 373-84, 2005.
492)  Jia Y, Guo GL, Surapureddi S, Sarkar J, Qi C, Guo D, Xia J, Kashireddi P, Yu S, Cho YW, Rao MS, Kemper B, Ge K, Gonzalez FJ, Reddy JK.
Transcription coactivator peroxisome proliferator-activated receptor-binding protein/mediator 1 deficiency abrogates acetaminophen hepatotoxicity.
Proc Natl Acad Sci U S A. 102: 12531-6, 2005.
493)  Cariou B, van Harmelen K, Duran-Sandoval D, van Dijk T, Grefhorst A, Bouchaert E, Fruchart JC, Gonzalez FJ, Kuipers F, Staels B.
Transient impairment of the adaptive response to fasting in FXR-deficient mice.
FEBS Lett. 579: 4076-80, 2005.
494)  Nukaya M, Takahashi Y, Gonzalez FJ, Kamataki T.
Aryl hydrocarbon receptor-mediated suppression of GH receptor and Janus kinase 2 expression in mice.
FEBS Lett. 558: 96-100, 2004.
495)  Gonzalez FJ.
Cytochrome P450 humanised mice.
Hum Genomics. 1: 300-6, 2004.
496)  Cheung C, Akiyama TE, Ward JM, Nicol CJ, Feigenbaum L, Vinson C, Gonzalez FJ.
Diminished hepatocellular proliferation in mice humanized for the nuclear receptor peroxisome proliferator-activated receptor alpha.
Cancer Res. 64: 3849-54, 2004.
497)  Matsusue K, Gavrilova O, Lambert G, Brewer HB, Ward JM, Inoue Y, LeRoith D, Gonzalez FJ.
Hepatic CCAAT/enhancer binding protein alpha mediates induction of lipogenesis and regulation of glucose homeostasis in leptin-deficient mice.
Mol Endocrinol. 18: 2751-64, 2004.
498)  Inoue Y, Yu AM, Inoue J, Gonzalez FJ.
Hepatocyte nuclear factor 4alpha is a central regulator of bile acid conjugation.
J Biol Chem. 279: 2480-9, 2004.
499)  Kamiya A, Inoue Y, Kodama T, Gonzalez FJ.
Hepatocyte nuclear factors 1alpha and 4alpha control expression of proline oxidase in adult liver.
FEBS Lett. 578: 63-8, 2004.
500)  Andreola F, Hayhurst GP, Luo G, Ferguson SS, Gonzalez FJ, Goldstein JA, De Luca LM.
Mouse liver CYP2C39 is a novel retinoic acid 4-hydroxylase. Its down-regulation offers a molecular basis for liver retinoid accumulation and fibrosis in aryl hydrocarbon receptor-null mice.
J Biol Chem. 279: 3434-8, 2004.
501)  Graells J, Vinyals A, Figueras A, Llorens A, Moreno A, Marcoval J, Gonzalez FJ, Fabra A.
Overproduction of VEGF concomitantly expressed with its receptors promotes growth and survival of melanoma cells through MAPK and PI3K signaling.
J Invest Dermatol. 123: 1151-61, 2004.
502)  Paolini M, Sapone A, Gonzalez FJ.
Parkinson's disease, pesticides and individual vulnerability.
Trends Pharmacol Sci. 25: 124-9, 2004.
503)  Nakajima T, Kamijo Y, Tanaka N, Sugiyama E, Tanaka E, Kiyosawa K, Fukushima Y, Peters JM, Gonzalez FJ, Aoyama T.
Peroxisome proliferator-activated receptor alpha protects against alcohol-induced liver damage.
Hepatology. 40: 972-80, 2004.
504)  Yang Q, Gonzalez FJ.
Peroxisome proliferator-activated receptor alpha regulates B lymphocyte development via an indirect pathway in mice.
Biochemical pharmacology. 68: 2143-50, 2004.
505)  Kim DJ, Akiyama TE, Harman FS, Burns AM, Shan W, Ward JM, Kennett MJ, Gonzalez FJ, Peters JM.
Peroxisome proliferator-activated receptor beta (delta)-dependent regulation of ubiquitin C expression contributes to attenuation of skin carcinogenesis.
J Biol Chem. 279: 23719-27, 2004.
506)  Akiyama TE, Lambert G, Nicol CJ, Matsusue K, Peters JM, Brewer HB, Gonzalez FJ.
Peroxisome proliferator-activated receptor beta/delta regulates very low density lipoprotein production and catabolism in mice on a Western diet.
J Biol Chem. 279: 20874-81, 2004.
507)  Harman FS, Nicol CJ, Marin HE, Ward JM, Gonzalez FJ, Peters JM.
Peroxisome proliferator-activated receptor-delta attenuates colon carcinogenesis.
Nat Med. 10: 481-3, 2004.
508)  Zhang Y, Castellani LW, Sinal CJ, Gonzalez FJ, Edwards PA.
Peroxisome proliferator-activated receptor-gamma coactivator 1alpha (PGC-1alpha) regulates triglyceride metabolism by activation of the nuclear receptor FXR.
Genes Dev. 18: 157-69, 2004.
509)  Matsusue K, Peters JM, Gonzalez FJ.
PPARbeta/delta potentiates PPARgamma-stimulated adipocyte differentiation.
FASEB J. 18: 1477-9, 2004.
510)  Nicol CJ, Yoon M, Ward JM, Yamashita M, Fukamachi K, Peters JM, Gonzalez FJ.
PPARgamma influences susceptibility to DMBA-induced mammary, ovarian and skin carcinogenesis.
Carcinogenesis. 25: 1747-55, 2004.
511)  Ward JM, Nikolov NP, Tschetter JR, Kopp JB, Gonzalez FJ, Kimura S, Siegel RM.
Progressive glomerulonephritis and histiocytic sarcoma associated with macrophage functional defects in CYP1B1-deficient mice.
Toxicol Pathol. 32: 710-8, 2004.
512)  Miyazaki M, Dobrzyn A, Sampath H, Lee SH, Man WC, Chu K, Peters JM, Gonzalez FJ, Ntambi JM.
Reduced adiposity and liver steatosis by stearoyl-CoA desaturase deficiency are independent of peroxisome proliferator-activated receptor-alpha.
J Biol Chem. 279: 35017-24, 2004.
513)  Maeda T, Miyata M, Yotsumoto T, Kobayashi D, Nozawa T, Toyama K, Gonzalez FJ, Yamazoe Y, Tamai I.
Regulation of drug transporters by the farnesoid X receptor in mice.
Mol Pharm. 1: 281-9, 2004.
514)  Andreola F, Calvisi DF, Elizondo G, Jakowlew SB, Mariano J, Gonzalez FJ, De Luca LM.
Reversal of liver fibrosis in aryl hydrocarbon receptor null mice by dietary vitamin A depletion.
Hepatology. 39: 157-66, 2004.
515)  Nebert DW, Dalton TP, Okey AB, Gonzalez FJ.
Role of aryl hydrocarbon receptor-mediated induction of the CYP1 enzymes in environmental toxicity and cancer.
J Biol Chem. 279: 23847-50, 2004.
516)  Peterson TC, Peterson MR, Wornell PA, Blanchard MG, Gonzalez FJ.
Role of CYP1A2 and CYP2E1 in the pentoxifylline ciprofloxacin drug interaction.
Biochem Pharmacol. 68: 395-402, 2004.
517)  Wolf KK, Wood SG, Bement JL, Sinclair PR, Wrighton SA, Jeffery E, Gonzalez FJ, Sinclair JF.
Role of mouse CYP2E1 in the O-hydroxylation of p-nitrophenol: comparison of activities in hepatic microsomes from Cyp2e1(-/-) and wild-type mice.
Drug Metab Dispos. 32: 681-4, 2004.
518)  Takemoto K, Nakajima M, Fujiki Y, Katoh M, Gonzalez FJ, Yokoi T.
Role of the aryl hydrocarbon receptor and Cyp1b1 in the antiestrogenic activity of 2,3,7,8-tetrachlorodibenzo-p-dioxin.
Arch Toxicol. 78: 309-15, 2004.
519)  Gonzalez FJ, Rueda A, Sevilla I, Alonso L, Villarreal V, Torres E, Alba E.
Shift in the balance between circulating thrombospondin-1 and vascular endothelial growth factor in cancer patients: relationship to platelet alpha-granule content and primary activation.
Int J Biol Markers. 19: 221-8, 2004.
520)  Jiang YJ, Lu B, Xu FY, Gartshore J, Taylor WA, Halayko AJ, Gonzalez FJ, Takasaki J, Choy PC, Hatch GM.
Stimulation of cardiac cardiolipin biosynthesis by PPARalpha activation.
J Lipid Res. 45: 244-52, 2004.
521)  Yubero P, Hondares E, Carmona MC, Rossell M, Gonzalez FJ, Iglesias R, Giralt M, Villarroya F.
The developmental regulation of peroxisome proliferator-activated receptor-gamma coactivator-1alpha expression in the liver is partially dissociated from the control of gluconeogenesis and lipid catabolism.
Endocrinology. 145: 4268-77, 2004.
522)  Peters JM, Kato S, Gonzalez FJ.
The United States-Japan workshop on: The role of nuclear receptors in carcinogenesis.
Mol Carcinog. 41: 77, 2004.
523)  Shimizu M, Takeshita A, Tsukamoto T, Gonzalez FJ, Osumi T.
Tissue-selective, bidirectional regulation of PEX11 alpha and perilipin genes through a common peroxisome proliferator response element.
Mol Cell Biol. 24: 1313-23, 2004.
524)  Kamiya A, Gonzalez FJ.
TNF-alpha regulates mouse fetal hepatic maturation induced by oncostatin M and extracellular matrices.
Hepatology. 40: 527-36, 2004.
525)  Jia Y, Qi C, Kashireddi P, Surapureddi S, Zhu YJ, Rao MS, Le Roith D, Chambon P, Gonzalez FJ, Reddy JK.
Transcription coactivator PBP, the peroxisome proliferator-activated receptor (PPAR)-binding protein, is required for PPARalpha-regulated gene expression in liver.
J Biol Chem. 279: 24427-34, 2004.
526)  Yu S, Matsusue K, Kashireddy P, Cao WQ, Yeldandi V, Yeldandi AV, Rao MS, Gonzalez FJ, Reddy JK.
Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor gamma1 (PPARgamma1) overexpression.
J. Biol. Chem. 278: 498-505, 2003.
527)  Takagi S, Tojo H, Tomita S, Sano S, Itami S, Hara M, Inoue S, Horie K, Kondoh G, Hosokawa K, Gonzalez FJ, Takeda J.
Alteration of the 4-sphingenine scaffolds of ceramides in keratinocyte-specific Arnt-deficient mice affects skin barrier function.
J Clin Invest. 112: 1372-82, 2003.
528)  Peters JM, Aoyama T, Burns AM, Gonzalez FJ.
Bezafibrate is a dual ligand for PPARalpha and PPARbeta: studies using null mice.
Biochim Biophys Acta. 1632: 80-9, 2003.
529)  Kimura S, Kawabe M, Yu A, Morishima H, Fernandez-Salguero P, Hammons GJ, Ward JM, Kadlubar FF, Gonzalez FJ.
Carcinogenesis of the food mutagen PhIP in mice is independent of CYP1A2.
Carcinogenesis. 24: 583-7, 2003.
530)  Zhu YJ, Crawford SE, Stellmach V, Dwivedi RS, Rao MS, Gonzalez FJ, Qi C, Reddy JK.
Coactivator PRIP, the peroxisome proliferator-activated receptor-interacting protein, is a modulator of placental, cardiac, hepatic, and embryonic development.
J. Biol. Chem. 278: 1986-90, 2003.
531)  Guo GL, Lambert G, Negishi M, Ward JM, Brewer HB, Kliewer SA, Gonzalez FJ, Sinal CJ.
Complementary roles of farnesoid X receptor, pregnane X receptor, and constitutive androstane receptor in protection against bile acid toxicity.
J Biol Chem. 278: 45062-71, 2003.
532)  Yu AM, Idle JR, Krausz KW, Küpfer A, Gonzalez FJ.
Contribution of individual cytochrome P450 isozymes to the O-demethylation of the psychotropic beta-carboline alkaloids harmaline and harmine.
J Pharmacol Exp Ther. 305: 315-22, 2003.
533)  Buters J, Quintanilla-Martinez L, Schober W, Soballa VJ, Hintermair J, Wolff T, Gonzalez FJ, Greim H.
CYP1B1 determines susceptibility to low doses of 7,12-dimethylbenz[a]anthracene-induced ovarian cancers in mice: correlation of CYP1B1-mediated DNA adducts with carcinogenicity.
Carcinogenesis. 24: 327-34, 2003.
534)  Tomita S, Ueno M, Sakamoto M, Kitahama Y, Ueki M, Maekawa N, Sakamoto H, Gassmann M, Kageyama R, Ueda N, Gonzalez FJ, Takahama Y.
Defective brain development in mice lacking the Hif-1alpha gene in neural cells.
Mol Cell Biol. 23: 6739-49, 2003.
535)  Granvil CP, Yu AM, Elizondo G, Akiyama TE, Cheung C, Feigenbaum L, Krausz KW, Gonzalez FJ.
Expression of the human CYP3A4 gene in the small intestine of transgenic mice: in vitro metabolism and pharmacokinetics of midazolam.
Drug Metab Dispos. 31: 548-58, 2003.
536)  Claudel T, Inoue Y, Barbier O, Duran-Sandoval D, Kosykh V, Fruchart J, Fruchart JC, Gonzalez FJ, Staels B.
Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression.
Gastroenterology. 125: 544-55, 2003.
537)  Bauer AK, Faiola B, Abernethy DJ, Marchan R, Pluta LJ, Wong VA, Roberts K, Jaiswal AK, Gonzalez FJ, Butterworth BE, Borghoff S, Parkinson H, Everitt J, Recio L.
Genetic susceptibility to benzene-induced toxicity: role of NADPH: quinone oxidoreductase-1.
Cancer Res. 63: 929-35, 2003.
538)  Lash LH, Hines RN, Gonzalez FJ, Zacharewski TR, Rothstein MA.
Genetics and susceptibility to toxic chemicals: do you (or should you) know your genetic profile?.
J. Pharmacol. Exp. Ther. 305: 403-9, 2003.
539)  Cheung C, Akiyama TE, Kudo G, Gonzalez FJ.
Hepatic expression of cytochrome P450s in hepatocyte nuclear factor 1-alpha (HNF1alpha)-deficient mice.
Biochem Pharmacol. 66: 2011-20, 2003.
540)  Hu M, Krausz K, Chen J, Ge X, Li J, Gelboin HL, Gonzalez FJ.
Identification of CYP1A2 as the main isoform for the phase I hydroxylated metabolism of genistein and a prodrug converting enzyme of methylated isoflavones.
Drug Metab Dispos. 31: 924-31, 2003.
541)  Tanaka N, Hora K, Makishima H, Kamijo Y, Kiyosawa K, Gonzalez FJ, Aoyama T.
In vivo stabilization of nuclear retinoid X receptor alpha in the presence of peroxisome proliferator-activated receptor alpha.
FEBS Lett. 543: 120-4, 2003.
542)  Gavrilova O, Haluzik M, Matsusue K, Cutson JJ, Johnson L, Dietz KR, Nicol CJ, Vinson C, Gonzalez FJ, Reitman ML.
Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass.
J Biol Chem. 278: 34268-76, 2003.
543)  Chen F, Ma L, Dawson PA, Sinal CJ, Sehayek E, Gonzalez FJ, Breslow J, Ananthanarayanan M, Shneider BL.
Liver receptor homologue-1 mediates species- and cell line-specific bile acid-dependent negative feedback regulation of the apical sodium-dependent bile acid transporter.
J. Biol. Chem. 278: 19909-16, 2003.
544)  Matsusue K, Haluzik M, Lambert G, Yim SH, Gavrilova O, Ward JM, Brewer B, Reitman ML, Gonzalez FJ.
Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes.
J Clin Invest. 111: 737-47, 2003.
545)  Bauer AK, Faiola B, Abernethy DJ, Marchan R, Pluta LJ, Wong VA, Gonzalez FJ, Butterworth BE, Borghoff SJ, Everitt JI, Recio L.
Male mice deficient in microsomal epoxide hydrolase are not susceptible to benzene-induced toxicity.
Toxicol. Sci. 72: 201-9, 2003.
546)  Yim SH, Ward JM, Dragan Y, Yamada A, Scacheri PC, Kimura S, Gonzalez FJ.
Microarray analysis using amplified mRNA from laser capture microdissection of microscopic hepatocellular precancerous lesions and frozen hepatocellular carcinomas reveals unique and consistent gene expression profiles.
Toxicol Pathol. 31: 295-303, 2003.
547)  Libby RT, Smith RS, Savinova OV, Zabaleta A, Martin JE, Gonzalez FJ, John SW.
Modification of ocular defects in mouse developmental glaucoma models by tyrosinase.
Science. 299: 1578-81, 2003.
548)  Norris AW, Chen L, Fisher SJ, Szanto I, Ristow M, Jozsi AC, Hirshman MF, Rosen ED, Goodyear LJ, Gonzalez FJ, Spiegelman BM, Kahn CR.
Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones.
J Clin Invest. 112: 608-18, 2003.
549)  Nöhammer C, Brunner F, Wölkart G, Staber PB, Steyrer E, Gonzalez FJ, Zechner R, Hoefler G.
Myocardial dysfunction and male mortality in peroxisome proliferator-activated receptor alpha knockout mice overexpressing lipoprotein lipase in muscle.
Lab. Invest. 83: 259-69, 2003.
550)  Kondraganti SR, Fernandez-Salguero P, Gonzalez FJ, Ramos KS, Jiang W, Moorthy B.
Polycyclic aromatic hydrocarbon-inducible DNA adducts: evidence by 32P-postlabeling and use of knockout mice for Ah receptor-independent mechanisms of metabolic activation in vivo.
Int J Cancer. 103: 5-11, 2003.
551)  Welch JS, Ricote M, Akiyama TE, Gonzalez FJ, Glass CK.
PPARgamma and PPARdelta negatively regulate specific subsets of lipopolysaccharide and IFN-gamma target genes in macrophages.
Proc Natl Acad Sci U S A. 100: 6712-7, 2003.
552)  Kitada H, Miyata M, Nakamura T, Tozawa A, Honma W, Shimada M, Nagata K, Sinal CJ, Guo GL, Gonzalez FJ, Yamazoe Y.
Protective role of hydroxysteroid sulfotransferase in lithocholic acid-induced liver toxicity.
J Biol Chem. 278: 17838-44, 2003.
553)  Yu AM, Idle JR, Byrd LG, Krausz KW, Küpfer A, Gonzalez FJ.
Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6.
Pharmacogenetics. 13: 173-81, 2003.
554)  Rhee J, Inoue Y, Yoon JC, Puigserver P, Fan M, Gonzalez FJ, Spiegelman BM.
Regulation of hepatic fasting response by PPARgamma coactivator-1alpha (PGC-1): requirement for hepatocyte nuclear factor 4alpha in gluconeogenesis.
Proc Natl Acad Sci U S A. 100: 4012-7, 2003.
555)  Akiyama TE, Gonzalez FJ.
Regulation of P450 genes by liver-enriched transcription factors and nuclear receptors.
Biochim Biophys Acta. 1619: 223-34, 2003.
556)  Wagner M, Fickert P, Zollner G, Fuchsbichler A, Silbert D, Tsybrovskyy O, Zatloukal K, Guo GL, Schuetz JD, Gonzalez FJ, Marschall HU, Denk H, Trauner M.
Role of farnesoid X receptor in determining hepatic ABC transporter expression and liver injury in bile duct-ligated mice.
Gastroenterology. 125: 825-38, 2003.
557)  Gonzalez FJ.
Role of gene knockout and transgenic mice in the study of xenobiotic metabolism.
Drug Metab Rev. 35: 319-35, 2003.
558)  Zollner G, Fickert P, Fuchsbichler A, Silbert D, Wagner M, Arbeiter S, Gonzalez FJ, Marschall HU, Zatloukal K, Denk H, Trauner M.
Role of nuclear bile acid receptor, FXR, in adaptive ABC transporter regulation by cholic and ursodeoxycholic acid in mouse liver, kidney and intestine.
J. Hepatol. 39: 480-8, 2003.
559)  Kamiya A, Inoue Y, Gonzalez FJ.
Role of the hepatocyte nuclear factor 4alpha in control of the pregnane X receptor during fetal liver development.
Hepatology. 37: 1375-84, 2003.
560)  Yu AM, Idle JR, Herraiz T, Küpfer A, Gonzalez FJ.
Screening for endogenous substrates reveals that CYP2D6 is a 5-methoxyindolethylamine O-demethylase.
Pharmacogenetics. 13: 307-19, 2003.
561)  Guo H, Wei J, Inoue Y, Gonzalez FJ, Kuo PC.
Serine/threonine phosphorylation regulates HNF-4alpha-dependent redox-mediated iNOS expression in hepatocytes.
Am J Physiol Cell Physiol. 284: C1090-9, 2003.
562)  Gonzalez FJ, Kimura S.
Study of P450 function using gene knockout and transgenic mice.
Arch Biochem Biophys. 409: 153-8, 2003.
563)  Tomita S, Jiang HB, Ueno T, Takagi S, Tohi K, Maekawa S, Miyatake A, Furukawa A, Gonzalez FJ, Takeda J, Ichikawa Y, Takahama Y.
T cell-specific disruption of arylhydrocarbon receptor nuclear translocator (Arnt) gene causes resistance to 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced thymic involution.
J Immunol. 171: 4113-20, 2003.
564)  Rosen ED, Kulkarni RN, Sarraf P, Ozcan U, Okada T, Hsu CH, Eisenman D, Magnuson MA, Gonzalez FJ, Kahn CR, Spiegelman BM.
Targeted elimination of peroxisome proliferator-activated receptor gamma in beta cells leads to abnormalities in islet mass without compromising glucose homeostasis.
Mol Cell Biol. 23: 7222-9, 2003.
565)  Lambert G, Amar MJ, Guo G, Brewer HB, Gonzalez FJ, Sinal CJ.
The farnesoid X-receptor is an essential regulator of cholesterol homeostasis.
J Biol Chem. 278: 2563-70, 2003.
566)  Tirona RG, Lee W, Leake BF, Lan LB, Cline CB, Lamba V, Parviz F, Duncan SA, Inoue Y, Gonzalez FJ, Schuetz EG, Kim RB.
The orphan nuclear receptor HNF4alpha determines PXR- and CAR-mediated xenobiotic induction of CYP3A4.
Nat Med. 9: 220-4, 2003.
567)  Yu AM, Granvil CP, Haining RL, Krausz KW, Corchero J, Küpfer A, Idle JR, Gonzalez FJ.
The relative contribution of monoamine oxidase and cytochrome p450 isozymes to the metabolic deamination of the trace amine tryptamine.
J Pharmacol Exp Ther. 304: 539-46, 2003.
568)  Elizondo G, Gonzalez FJ.
Understanding molecular mechanisms of toxicity and carcinogensis using gene knockout and transgenic mouse models.
Transgenic Models in Pharmacology, Handbook of Experimental Pharmacology Vol. 159 (S. Offermanns, L. Hein, Eds.). Springer-Verlag, Berlin Heidelberg New York: 640-660, 2003.
569)  Granvil CP, Krausz KW, Gelboin HV, Idle JR, Gonzalez FJ.
4-Hydroxylation of debrisoquine by human CYP1A1 and its inhibition by quinidine and quinine.
J Pharmacol Exp Ther. 301: 1025-32, 2002.
570)  Urizar NL, Liverman AB, Dodds DT, Silva FV, Ordentlich P, Yan Y, Gonzalez FJ, Heyman RA, Mangelsdorf DJ, Moore DD.
A natural product that lowers cholesterol as an antagonist ligand for FXR.
Science. 296: 1703-6, 2002.
571)  Girnun GD, Smith WM, Drori S, Sarraf P, Mueller E, Eng C, Nambiar P, Rosenberg DW, Bronson RT, Edelmann W, Kucherlapati R, Gonzalez FJ, Spiegelman BM.
APC-dependent suppression of colon carcinogenesis by PPARgamma.
Proc Natl Acad Sci U S A. 99: 13771-6, 2002.
572)  Rosen ED, Hsu CH, Wang X, Sakai S, Freeman MW, Gonzalez FJ, Spiegelman BM.
C/EBPalpha induces adipogenesis through PPARgamma: a unified pathway.
Genes Dev. 16: 22-6, 2002.
573)  Courselaud B, Pigeon C, Inoue Y, Inoue J, Gonzalez FJ, Leroyer P, Gilot D, Boudjema K, Guguen-Guillouzo C, Brissot P, Loréal O, Ilyin G.
C/EBPalpha regulates hepatic transcription of hepcidin, an antimicrobial peptide and regulator of iron metabolism. Cross-talk between C/EBP pathway and iron metabolism.
J Biol Chem. 277: 41163-70, 2002.
574)  Akiyama TE, Sakai S, Lambert G, Nicol CJ, Matsusue K, Pimprale S, Lee YH, Ricote M, Glass CK, Brewer HB, Gonzalez FJ.
Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux.
Mol Cell Biol. 22: 2607-19, 2002.
575)  Buters JT, Mahadevan B, Quintanilla-Martinez L, Gonzalez FJ, Greim H, Baird WM, Luch A.
Cytochrome P450 1B1 determines susceptibility to dibenzo[a,l]pyrene-induced tumor formation.
Chem Res Toxicol. 15: 1127-35, 2002.
576)  Inoue Y, Hayhurst GP, Inoue J, Mori M, Gonzalez FJ.
Defective ureagenesis in mice carrying a liver-specific disruption of hepatocyte nuclear factor 4alpha (HNF4alpha ). HNF4alpha regulates ornithine transcarbamylase in vivo.
J Biol Chem. 277: 25257-65, 2002.
577)  Long DJ, Gaikwad A, Multani A, Pathak S, Montgomery CA, Gonzalez FJ, Jaiswal AK.
Disruption of the NAD(P)H:quinone oxidoreductase 1 (NQO1) gene in mice causes myelogenous hyperplasia.
Cancer Res. 62: 3030-6, 2002.
578)  Nammo T, Yamagata K, Hamaoka R, Zhu Q, Akiyama TE, Gonzalez FJ, Miyagawa J, Matsuzawa Y.
Expression profile of MODY3/HNF-1alpha protein in the developing mouse pancreas.
Diabetologia. 45: 1142-53, 2002.
579)  Sinal CJ, Gonzalez FJ.
Guggulsterone: an old approach to a new problem.
Trends Endocrinol Metab. 13: 275-6, 2002.
580)  Rao MS, Peters JM, Gonzalez FJ, Reddy JK.
Hepatic regeneration in peroxisome proliferator-activated receptor alpha-null mice after partial hepatectomy.
Hepatol Res. 22: 52-57, 2002.
581)  Kamijo Y, Hora K, Tanaka N, Usuda N, Kiyosawa K, Nakajima T, Gonzalez FJ, Aoyama T.
Identification of functions of peroxisome proliferator-activated receptor alpha in proximal tubules.
J Am Soc Nephrol. 13: 1691-702, 2002.
582)  Cui Y, Miyoshi K, Claudio E, Siebenlist UK, Gonzalez FJ, Flaws J, Wagner KU, Hennighausen L.
Loss of the peroxisome proliferation-activated receptor gamma (PPARgamma ) does not affect mammary development and propensity for tumor formation but leads to reduced fertility.
J Biol Chem. 277: 17830-5, 2002.
583)  Koffler LD, Fernstrom MJ, Akiyama TE, Gonzalez FJ, Ruch RJ.
Positive regulation of connexin32 transcription by hepatocyte nuclear factor-1alpha.
Arch Biochem Biophys. 407: 160-7, 2002.
584)  Miyata M, Motoki K, Tamura E, Furukawa M, Gonzalez FJ, Yamazoe Y.
Relative importance of maternal and embryonic microsomal epoxide hydrolase in 7,12-dimethylbenz[a]anthracene-induced developmental toxicity.
Biochem Pharmacol. 63: 1077-84, 2002.
585)  Akiyama TE, Baumann CT, Sakai S, Hager GL, Gonzalez FJ.
Selective intranuclear redistribution of PPAR isoforms by RXR alpha.
Mol Endocrinol. 16: 707-21, 2002.
586)  Narimatsu S, Takemi C, Tsuzuki D, Kataoka H, Yamamoto S, Shimada N, Suzuki S, Satoh T, Meyer UA, Gonzalez FJ.
Stereoselective metabolism of bufuralol racemate and enantiomers in human liver microsomes.
J Pharmacol Exp Ther. 303: 172-8, 2002.
587)  Le Provost F, Riedlinger G, Hee Yim S, Benedict J, Gonzalez FJ, Flaws J, Hennighausen L.
The aryl hydrocarbon receptor (AhR) and its nuclear translocator (Arnt) are dispensable for normal mammary gland development but are required for fertility.
Genesis. 32: 231-9, 2002.
588)  Louet JF, Hayhurst G, Gonzalez FJ, Girard J, Decaux JF.
The coactivator PGC-1 is involved in the regulation of the liver carnitine palmitoyltransferase I gene expression by cAMP in combination with HNF4 alpha and cAMP-response element-binding protein (CREB).
J Biol Chem. 277: 37991-8000, 2002.
589)  Gonzalez FJ.
The peroxisome proliferator-activated receptor alpha (PPARalpha): role in hepatocarcinogenesis.
Mol Cell Endocrinol. 193: 71-9, 2002.
590)  Sapone A, Paolini M, Biagi GL, Cantelli-Forti G, Gonzalez FJ.
The pressing need for combined genotype-phenotype analysis in clinical practice.
Trends Pharmacol Sci. 23: 260-1, 2002.
591)  Gonzalez FJ.
Transgenic models in xenobiotic metabolism and toxicology.
Toxicology. 181-182: 237-9, 2002.
592)  Hiraiwa H, Pan CJ, Lin B, Akiyama TE, Gonzalez FJ, Chou JY.
A molecular link between the common phenotypes of type 1 glycogen storage disease and HNF1alpha-null mice.
J Biol Chem. 276: 7963-7, 2001.
593)  Sinal CJ, Yoon M, Gonzalez FJ.
Antagonism of the actions of peroxisome proliferator-activated receptor-alpha by bile acids.
J Biol Chem. 276: 47154-62, 2001.
594)  Nukaya M, Takahashi Y, Gonzalez FJ, Kamataki T.
Aryl hydrocarbon receptor-mediated suppression of expression of the low-molecular-weight prekininogen gene in mice.
Biochem Biophys Res Commun. 287: 301-4, 2001.
595)  Sohn OS, Fiala ES, Requeijo SP, Weisburger JH, Gonzalez FJ.
Differential effects of CYP2E1 status on the metabolic activation of the colon carcinogens azoxymethane and methylazoxymethanol.
Cancer Res. 61: 8435-40, 2001.
596)  Schuetz EG, Strom S, Yasuda K, Lecureur V, Assem M, Brimer C, Lamba J, Kim RB, Ramachandran V, Komoroski BJ, Venkataramanan R, Cai H, Sinal CJ, Gonzalez FJ, Schuetz JD.
Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters, and cytochrome P450.
J Biol Chem. 276: 39411-8, 2001.
597)  Kiss A, Ortiz-Aguayo R, Sharp R, Merlino G, Thorgeirsson SS, Gonzalez FJ, Peters JM.
Evidence that reduction of hepatocyte growth factor (HGF) is not required for peroxisome proliferator-induced hepatocyte proliferation.
Carcinogenesis. 22: 975-9, 2001.
598)  Kast HR, Nguyen CM, Sinal CJ, Jones SA, Laffitte BA, Reue K, Gonzalez FJ, Willson TM, Edwards PA.
Farnesoid X-activated receptor induces apolipoprotein C-II transcription: a molecular mechanism linking plasma triglyceride levels to bile acids.
Mol Endocrinol. 15: 1720-8, 2001.
599)  Hayhurst GP, Lee YH, Lambert G, Ward JM, Gonzalez FJ.
Hepatocyte nuclear factor 4alpha (nuclear receptor 2A1) is essential for maintenance of hepatic gene expression and lipid homeostasis.
Mol Cell Biol. 21: 1393-403, 2001.
600)  Shih DQ, Bussen M, Sehayek E, Ananthanarayanan M, Shneider BL, Suchy FJ, Shefer S, Bollileni JS, Gonzalez FJ, Breslow JL, Stoffel M.
Hepatocyte nuclear factor-1alpha is an essential regulator of bile acid and plasma cholesterol metabolism.
Nat Genet. 27: 375-82, 2001.
601)  Yu S, Cao WQ, Kashireddy P, Meyer K, Jia Y, Hughes DE, Tan Y, Feng J, Yeldandi AV, Rao MS, Costa RH, Gonzalez FJ, Reddy JK.
Human peroxisome proliferator-activated receptor alpha (PPARalpha) supports the induction of peroxisome proliferation in PPARalpha-deficient mouse liver.
J Biol Chem. 276: 42485-91, 2001.
602)  Ward JM, Yoon M, Anver MR, Haines DC, Kudo G, Gonzalez FJ, Kimura S.
Hyalinosis and Ym1/Ym2 gene expression in the stomach and respiratory tract of 129S4/SvJae and wild-type and CYP1A2-null B6, 129 mice.
Am J Pathol. 158: 323-32, 2001.
603)  Michalik L, Desvergne B, Tan NS, Basu-Modak S, Escher P, Rieusset J, Peters JM, Kaya G, Gonzalez FJ, Zakany J, Metzger D, Chambon P, Duboule D, Wahli W.
Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR)alpha and PPARbeta mutant mice.
J Cell Biol. 154: 799-814, 2001.
604)  Peters JM, Park Y, Gonzalez FJ, Pariza MW.
Influence of conjugated linoleic acid on body composition and target gene expression in peroxisome proliferator-activated receptor alpha-null mice.
Biochim Biophys Acta. 1533: 233-42, 2001.
605)  Miyata M, Furukawa M, Takahashi K, Gonzalez FJ, Yamazoe Y.
Mechanism of 7,12-dimethylbenz[a]anthracene-induced immunotoxicity: role of metabolic activation at the target organ.
Jpn J Pharmacol. 86: 302-9, 2001.
606)  Cui X, Kawashima H, Barclay TB, Peters JM, Gonzalez FJ, Morgan ET, Strobel HW.
Molecular cloning and regulation of expression of two novel mouse CYP4F genes: expression in peroxisome proliferator-activated receptor alpha-deficient mice upon lipopolysaccharide and clofibrate challenges.
J Pharmacol Exp Ther. 296: 542-50, 2001.
607)  Krausz KW, Goldfarb I, Buters JT, Yang TJ, Gonzalez FJ, Gelboin HV.
Monoclonal antibodies specific and inhibitory to human cytochromes P450 2C8, 2C9, and 2C19.
Drug Metab Dispos. 29: 1410-23, 2001.
608)  Akiyama TE, Nicol CJ, Gonzalez FJ.
On par with PPARs.
Trends Genet. 17: 310-12, 2001.
609)  Corchero J, Pimprale S, Kimura S, Gonzalez FJ.
Organization of the CYP1A cluster on human chromosome 15: implications for gene regulation.
Pharmacogenetics. 11: 1-6, 2001.
610)  Dallongeville J, Baugé E, Tailleux A, Peters JM, Gonzalez FJ, Fruchart JC, Staels B.
Peroxisome proliferator-activated receptor alpha is not rate-limiting for the lipoprotein-lowering action of fish oil.
J Biol Chem. 276: 4634-9, 2001.
611)  Akiyama TE, Nicol CJ, Fievet C, Staels B, Ward JM, Auwerx J, Lee SS, Gonzalez FJ, Peters JM.
Peroxisome proliferator-activated receptor-alpha regulates lipid homeostasis, but is not associated with obesity: studies with congenic mouse lines.
J Biol Chem. 276: 39088-93, 2001.
612)  Rusyn I, Kadiiska MB, Dikalova A, Kono H, Yin M, Tsuchiya K, Mason RP, Peters JM, Gonzalez FJ, Segal BH, Holland SM, Thurman RG.
Phthalates rapidly increase production of reactive oxygen species in vivo: role of Kupffer cells.
Mol Pharmacol. 59: 744-50, 2001.
613)  Xu S, Zhu BT, Turan V, Rusyn I, Thurman R, Peters JM, Gonzalez FJ, Conney AH.
PPARalpha-dependent induction of liver microsomal esterification of estradiol and testosterone by a prototypical peroxisome proliferator.
Endocrinology. 142: 3554-7, 2001.
614)  Guerre-Millo M, Rouault C, Poulain P, André J, Poitout V, Peters JM, Gonzalez FJ, Fruchart JC, Reach G, Staels B.
PPARalpha-null mice are protected from high-fat diet-induced insulin resistance.
Diabetes. 50: 2809-14, 2001.
615)  Wan YY, Cai Y, Li J, Yuan Q, French B, Gonzalez FJ, French S.
Regulation of peroxisome proliferator activated receptor alpha-mediated pathways in alcohol fed cytochrome P450 2E1 deficient mice.
Hepatol Res. 19: 117-130, 2001.
616)  Lewitt MS, Brismar K, Wang J, Wivall-Helleryd IL, Sindelar P, Gonzalez FJ, Bergman T, Bobek GA.
Responses of insulin-like growth factor (IGF)-I and IGF-binding proteins to nutritional status in peroxisome proliferator-activated receptor-alpha knockout mice.
Growth Horm IGF Res. 11: 303-13, 2001.
617)  Corchero J, Granvil CP, Akiyama TE, Hayhurst GP, Pimprale S, Feigenbaum L, Idle JR, Gonzalez FJ.
The CYP2D6 humanized mouse: effect of the human CYP2D6 transgene and HNF4alpha on the disposition of debrisoquine in the mouse.
Mol Pharmacol. 60: 1260-7, 2001.
618)  Kersten S, Mandard S, Escher P, Gonzalez FJ, Tafuri S, Desvergne B, Wahli W.
The peroxisome proliferator-activated receptor alpha regulates amino acid metabolism.
FASEB J. 15: 1971-8, 2001.
619)  Wheeler MD, Kono H, Yin M, Nakagami M, Uesugi T, Arteel GE, Gäbele E, Rusyn I, Yamashina S, Froh M, Adachi Y, Iimuro Y, Bradford BU, Smutney OM, Connor HD, Mason RP, Goyert SM, Peters JM, Gonzalez FJ, Samulski RJ, Thurman RG.
The role of Kupffer cell oxidant production in early ethanol-induced liver disease.
Free Radic Biol Med. 31: 1544-9, 2001.
620)  Gonzalez FJ.
The use of gene knockout mice to unravel the mechanisms of toxicity and chemical carcinogenesis.
Toxicol Lett. 120: 199-208, 2001.
621)  Gonzalez FJ, Kimura S.
Understanding the role of xenobiotic-metabolism in chemical carcinogenesis using gene knockout mice.
Mutat Res. 477: 79-87, 2001.
622)  Ueno T, Tamura S, Frels WI, Shou M, Gonzalez FJ, Kimura S.
A transgenic mouse expressing human CYP1A2 in the pancreas.
Biochem Pharmacol. 60: 857-63, 2000.
623)  Elizondo G, Fernandez-Salguero P, Sheikh MS, Kim GY, Fornace AJ, Lee KS, Gonzalez FJ.
Altered cell cycle control at the G(2)/M phases in aryl hydrocarbon receptor-null embryo fibroblast.
Mol Pharmacol. 57: 1056-63, 2000.
624)  Krausz KW, Goldfarb I, Yang TJ, Gonzalez FJ, Gelboin HV.
An inhibitory monoclonal antibody to human cytochrome P450 that specifically binds and inhibits P4502C9II, an allelic variant of P4502C9 having a single amino acid change Arg144 Cys.
Xenobiotica. 30: 619-25, 2000.
625)  Kimura S, Gonzalez FJ.
Applications of genetically manipulated mice in pharmacogenetics and pharmacogenomics.
Pharmacology. 61: 147-53, 2000.
626)  Tohkin M, Fukuhara M, Elizondo G, Tomita S, Gonzalez FJ.
Aryl hydrocarbon receptor is required for p300-mediated induction of DNA synthesis by adenovirus E1A.
Mol Pharmacol. 58: 845-51, 2000.
627)  Sai Y, Dai R, Yang TJ, Krausz KW, Gonzalez FJ, Gelboin HV, Shou M.
Assessment of specificity of eight chemical inhibitors using cDNA-expressed cytochromes P450.
Xenobiotica. 30: 327-43, 2000.
628)  Corton JC, Lapinskas PJ, Gonzalez FJ.
Central role of PPARalpha in the mechanism of action of hepatocarcinogenic peroxisome proliferators.
Mutat Res. 448: 139-51, 2000.
629)  Kersten S, Mandard S, Tan NS, Escher P, Metzger D, Chambon P, Gonzalez FJ, Desvergne B, Wahli W.
Characterization of the fasting-induced adipose factor FIAF, a novel peroxisome proliferator-activated receptor target gene.
J Biol Chem. 275: 28488-93, 2000.
630)  Aitchison KJ, Jann MW, Zhao JH, Sakai T, Zaher H, Wolff K, Collier DA, Kerwin RW, Gonzalez FJ.
Clozapine pharmacokinetics and pharmacodynamics studied with Cyp1A2-null mice.
J Psychopharmacol. 14: 353-9, 2000.
631)  Tomita S, Sinal CJ, Yim SH, Gonzalez FJ.
Conditional disruption of the aryl hydrocarbon receptor nuclear translocator (Arnt) gene leads to loss of target gene induction by the aryl hydrocarbon receptor and hypoxia-inducible factor 1alpha.
Mol Endocrinol. 14: 1674-81, 2000.
632)  Watanabe K, Fujii H, Takahashi T, Kodama M, Aizawa Y, Ohta Y, Ono T, Hasegawa G, Naito M, Nakajima T, Kamijo Y, Gonzalez FJ, Aoyama T.
Constitutive regulation of cardiac fatty acid metabolism through peroxisome proliferator-activated receptor alpha associated with age-dependent cardiac toxicity.
Journal of biological chemistry. 275: 22293-9, 2000.
633)  Leclercq IA, Farrell GC, Field J, Bell DR, Gonzalez FJ, Robertson GR.
CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis.
J Clin Invest. 105: 1067-75, 2000.
634)  Sata F, Sapone A, Elizondo G, Stocker P, Miller VP, Zheng W, Raunio H, Crespi CL, Gonzalez FJ.
CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity.
Clin Pharmacol Ther. 67: 48-56, 2000.
635)  Heidel SM, MacWilliams PS, Baird WM, Dashwood WM, Buters JT, Gonzalez FJ, Larsen MC, Czuprynski CJ, Jefcoate CR.
Cytochrome P4501B1 mediates induction of bone marrow cytotoxicity and preleukemia cells in mice treated with 7,12-dimethylbenz[a]anthracene.
Cancer Res. 60: 3454-60, 2000.
636)  Portilla D, Dai G, Peters JM, Gonzalez FJ, Crew MD, Proia AD.
Etomoxir-induced PPARalpha-modulated enzymes protect during acute renal failure.
Am J Physiol Renal Physiol. 278: F667-75, 2000.
637)  Pan DA, Mater MK, Thelen AP, Peters JM, Gonzalez FJ, Jump DB.
Evidence against the peroxisome proliferator-activated receptor alpha (PPARalpha) as the mediator for polyunsaturated fatty acid suppression of hepatic L-pyruvate kinase gene transcription.
J Lipid Res. 41: 742-51, 2000.
638)  DeLuca JG, Doebber TW, Kelly LJ, Kemp RK, Molon-Noblot S, Sahoo SP, Ventre J, Wu MS, Peters JM, Gonzalez FJ, Moller DE.
Evidence for peroxisome proliferator-activated receptor (PPAR)alpha-independent peroxisome proliferation: effects of PPARgamma/delta-specific agonists in PPARalpha-null mice.
Mol Pharmacol. 58: 470-6, 2000.
639)  Elizondo G, Corchero J, Sterneck E, Gonzalez FJ.
Feedback inhibition of the retinaldehyde dehydrogenase gene ALDH1 by retinoic acid through retinoic acid receptor alpha and CCAAT/enhancer-binding protein beta.
J Biol Chem. 275: 39747-53, 2000.
640)  Wu X, Peters JM, Gonzalez FJ, Prasad HS, Rohrer MD, Gimble JM.
Frequency of stromal lineage colony forming units in bone marrow of peroxisome proliferator-activated receptor-alpha-null mice.
Bone. 26: 21-6, 2000.
641)  Iba MM, Fung J, Gonzalez FJ.
Functional Cyp2e1 is required for substantial in vivo formation of 2,5-hexanedione from n-hexane in the mouse.
Arch Toxicol. 74: 582-6, 2000.
642)  Peters JM, Lee SS, Li W, Ward JM, Gavrilova O, Everett C, Reitman ML, Hudson LD, Gonzalez FJ.
Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta(delta).
Mol Cell Biol. 20: 5119-28, 2000.
643)  Peterson TC, Hodgson P, Fernandez-Salguero P, Neumeister M, Gonzalez FJ.
Hepatic fibrosis and cytochrome P450: experimental models of fibrosis compared to AHR knockout mice.
Hepatol Res. 17: 112-125, 2000.
644)  Echizen H, Tanizaki M, Tatsuno J, Chiba K, Berwick T, Tani M, Gonzalez FJ, Ishizaki T.
Identification of CYP3A4 as the enzyme involved in the mono-N-dealkylation of disopyramide enantiomers in humans.
Drug Metab Dispos. 28: 937-44, 2000.
645)  Aitchison KJ, Gonzalez FJ, Quattrochi LC, Sapone A, Zhao JH, Zaher H, Elizondo G, Bryant C, Munro J, Collier DA, Makoffa AI, Kerwin RW.
Identification of novel polymorphisms in the 5' flanking region of CYP1A2, characterization of interethnic variability, and investigation of their functional significance.
Pharmacogenetics. 10: 695-704, 2000.
646)  Turunen M, Peters JM, Gonzalez FJ, Schedin S, Dallner G.
Influence of peroxisome proliferator-activated receptor alpha on ubiquinone biosynthesis.
J Mol Biol. 297: 607-14, 2000.
647)  Hunt MC, Lindquist PJ, Peters JM, Gonzalez FJ, Diczfalusy U, Alexson SE.
Involvement of the peroxisome proliferator-activated receptor alpha in regulating long-chain acyl-CoA thioesterases.
J Lipid Res. 41: 814-23, 2000.
648)  Peters JM, Rusyn I, Rose ML, Gonzalez FJ, Thurman RG.
Peroxisome proliferator-activated receptor alpha is restricted to hepatic parenchymal cells, not Kupffer cells: implications for the mechanism of action of peroxisome proliferators in hepatocarcinogenesis.
Carcinogenesis. 21: 823-6, 2000.
649)  Akiyama TE, Ward JM, Gonzalez FJ.
Regulation of the liver fatty acid-binding protein gene by hepatocyte nuclear factor 1alpha (HNF1alpha). Alterations in fatty acid homeostasis in HNF1alpha-deficient mice.
J Biol Chem. 275: 27117-22, 2000.
650)  Sinclair PR, Gorman N, Walton HS, Bement WJ, Szakacs J, Gonzalez FJ, Dalton TP, Nebert DW, Sinclair JF.
Relative roles of CYP2E1 and CYP1A2 in mouse uroporphyria caused by acetone.
Arch Biochem Biophys. 384: 383-90, 2000.
651)  Nakajima T, Kamijo Y, Usuda N, Liang Y, Fukushima Y, Kametani K, Gonzalez FJ, Aoyama T.
Sex-dependent regulation of hepatic peroxisome proliferation in mice by trichloroethylene via peroxisome proliferator-activated receptor alpha (PPARalpha).
Carcinogenesis. 21: 677-82, 2000.
652)  Sinclair JF, Szakacs JG, Wood SG, Walton HS, Bement JL, Gonzalez FJ, Jeffery EH, Wrighton SA, Bement WJ, Sinclair PR.
Short-term treatment with alcohols causes hepatic steatosis and enhances acetaminophen hepatotoxicity in Cyp2e1(-/-) mice.
Toxicol Appl Pharmacol. 168: 114-22, 2000.
653)  Narimatsu S, Kobayashi N, Masubuchi Y, Horie T, Kakegawa T, Kobayashi H, Hardwick JP, Gonzalez FJ, Shimada N, Ohmori S, Kitada M, Asaoka K, Kataoka H, Yamamoto S, Satoh T.
Species difference in enantioselectivity for the oxidation of propranolol by cytochrome P450 2D enzymes.
Chem Biol Interact. 127: 73-90, 2000.
654)  Hasmall SC, James NH, Macdonald N, Gonzalez FJ, Peters JM, Roberts RA.
Suppression of mouse hepatocyte apoptosis by peroxisome proliferators: role of PPARalpha and TNFalpha.
Mutat Res. 448: 193-200, 2000.
655)  Sinal CJ, Miyata M, Tohkin M, Nagata K, Bend JR, Gonzalez FJ.
Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation.
Journal of biological chemistry. 275: 40504-10, 2000.
656)  Sinal CJ, Tohkin M, Miyata M, Ward JM, Lambert G, Gonzalez FJ.
Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis.
Cell. 102: 731-44, 2000.
657)  Sapone A, Peters JM, Sakai S, Tomita S, Papiha SS, Dai R, Friedman FK, Gonzalez FJ.
The human peroxisome proliferator-activated receptor alpha gene: identification and functional characterization of two natural allelic variants.
Pharmacogenetics. 10: 321-33, 2000.
658)  Holden PR, Hasmall SC, James NH, West DR, Brindle RD, Gonzalez FJ, Peters JM, Roberts RA.
Tumour necrosis factor alpha (TNFalpha): role in suppression of apoptosis by the peroxisome proliferator nafenopin.
Cell Mol Biol (Noisy-le-grand). 46: 29-39, 2000.
659)  Shou M, Lu T, Krausz KW, Sai Y, Yang T, Korzekwa KR, Gonzalez FJ, Gelboin HV.
Use of inhibitory monoclonal antibodies to assess the contribution of cytochromes P450 to human drug metabolism.
Eur J Pharmacol. 394: 199-209, 2000.
660)  Heidel SM, Holston K, Buters JT, Gonzalez FJ, Jefcoate CR, Czupyrynski CJ.
Bone marrow stromal cell cytochrome P4501B1 is required for pre-B cell apoptosis induced by 7,12-dimethylbenz[a]anthracene.
Mol Pharmacol. 56: 1317-23, 1999.
661)  Kono H, Bradford BU, Yin M, Sulik KK, Koop DR, Peters JM, Gonzalez FJ, McDonald T, Dikalova A, Kadiiska MB, Mason RP, Thurman RG.
CYP2E1 is not involved in early alcohol-induced liver injury.
Am J Physiol. 277: G1259-67, 1999.
662)  Chida M, Yokoi T, Kosaka Y, Chiba K, Nakamura H, Ishizaki T, Yokota J, Kinoshita M, Sato K, Inaba M, Aoki Y, Gonzalez FJ, Kamataki T.
Genetic polymorphism of CYP2D6 in the Japanese population.
Pharmacogenetics. 9: 601-5, 1999.
663)  Sumner SC, Fennell TR, Moore TA, Chanas B, Gonzalez F, Ghanayem BI.
Role of cytochrome P450 2E1 in the metabolism of acrylamide and acrylonitrile in mice.
Chemical research in toxicology. 12: 1110-6, 1999.
664)  Fernandez-Salguero P, Pineau T, Hilbert DM, McPhail T, Lee SS, Kimura S, Nebert DW, Rudikoff S, Ward JM, Gonzalez FJ.
Immune system impairment and hepatic fibrosis in mice lacking the dioxin-binding Ah receptor.
Science. 268: 722-6, 1995.
665)  Lee SS, Pineau T, Drago J, Lee EJ, Owens JW, Kroetz DL, Fernandez-Salguero PM, Westphal H, Gonzalez FJ.
Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators.
Mol Cell Biol. 15: 3012-22, 1995.
666)  Gonzalez FJ, Skoda RC, Kimura S, Umeno M, Zanger UM, Nebert DW, Gelboin HV, Hardwick JP, Meyer UA.
Characterization of the common genetic defect in humans deficient in debrisoquine metabolism.
Nature. 331: 442-6, 1988.
Click Here to View Collapsed Bibliography.

This page was last updated on 1/21/2014.